WO2005086798A2 - Improved interleukin-2 muteins - Google Patents
Improved interleukin-2 muteins Download PDFInfo
- Publication number
- WO2005086798A2 WO2005086798A2 PCT/US2005/007517 US2005007517W WO2005086798A2 WO 2005086798 A2 WO2005086798 A2 WO 2005086798A2 US 2005007517 W US2005007517 W US 2005007517W WO 2005086798 A2 WO2005086798 A2 WO 2005086798A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- mutein
- seq
- alanyl
- des
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 524
- 102000000588 Interleukin-2 Human genes 0.000 title claims abstract description 523
- 230000001976 improved effect Effects 0.000 title claims description 57
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract description 658
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 275
- 210000004027 cell Anatomy 0.000 claims abstract description 224
- 238000000034 method Methods 0.000 claims abstract description 78
- 238000011282 treatment Methods 0.000 claims abstract description 58
- 230000001404 mediated effect Effects 0.000 claims abstract description 57
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 54
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 51
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 51
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 230000001988 toxicity Effects 0.000 claims abstract description 22
- 231100000419 toxicity Toxicity 0.000 claims abstract description 22
- 239000013604 expression vector Substances 0.000 claims abstract description 21
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 102000055277 human IL2 Human genes 0.000 claims abstract description 12
- 210000000987 immune system Anatomy 0.000 claims abstract description 12
- 239000003937 drug carrier Substances 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 10
- 230000004936 stimulating effect Effects 0.000 claims abstract description 7
- 230000002708 enhancing effect Effects 0.000 claims abstract description 5
- 230000004663 cell proliferation Effects 0.000 claims description 144
- 230000006433 tumor necrosis factor production Effects 0.000 claims description 129
- 238000006467 substitution reaction Methods 0.000 claims description 124
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 111
- 125000003729 nucleotide group Chemical group 0.000 claims description 87
- 239000002773 nucleotide Substances 0.000 claims description 86
- 238000003556 assay Methods 0.000 claims description 84
- 229920001184 polypeptide Polymers 0.000 claims description 81
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 81
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 81
- 230000000770 proinflammatory effect Effects 0.000 claims description 80
- 238000004166 bioassay Methods 0.000 claims description 79
- 230000000694 effects Effects 0.000 claims description 76
- 230000016396 cytokine production Effects 0.000 claims description 74
- 230000035755 proliferation Effects 0.000 claims description 53
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 50
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 49
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 48
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 44
- 108020004705 Codon Proteins 0.000 claims description 43
- 102200136470 rs35114462 Human genes 0.000 claims description 41
- 235000001014 amino acid Nutrition 0.000 claims description 40
- 230000001965 increasing effect Effects 0.000 claims description 39
- 230000003013 cytotoxicity Effects 0.000 claims description 36
- 231100000135 cytotoxicity Toxicity 0.000 claims description 36
- 230000002829 reductive effect Effects 0.000 claims description 36
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 32
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 31
- 102220618307 YLP motif-containing protein 1_F42E_mutation Human genes 0.000 claims description 30
- 102000004127 Cytokines Human genes 0.000 claims description 27
- 108090000695 Cytokines Proteins 0.000 claims description 27
- 229960004641 rituximab Drugs 0.000 claims description 26
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 22
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 20
- 201000001441 melanoma Diseases 0.000 claims description 20
- 235000004279 alanine Nutrition 0.000 claims description 18
- 102220589633 RING finger protein 37_L40R_mutation Human genes 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 17
- 230000037430 deletion Effects 0.000 claims description 17
- 230000006698 induction Effects 0.000 claims description 17
- 238000010171 animal model Methods 0.000 claims description 16
- 230000001461 cytolytic effect Effects 0.000 claims description 15
- 230000000259 anti-tumor effect Effects 0.000 claims description 14
- 231100000682 maximum tolerated dose Toxicity 0.000 claims description 14
- 230000036760 body temperature Effects 0.000 claims description 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 13
- 235000018417 cysteine Nutrition 0.000 claims description 13
- 230000002792 vascular Effects 0.000 claims description 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 11
- 230000003247 decreasing effect Effects 0.000 claims description 11
- 102220546836 Nuclear pore complex protein Nup85_L19D_mutation Human genes 0.000 claims description 10
- 230000002147 killing effect Effects 0.000 claims description 10
- 238000005259 measurement Methods 0.000 claims description 10
- 102200000390 rs121917859 Human genes 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- 102220570925 N-acetylgalactosamine-6-sulfatase_L36P_mutation Human genes 0.000 claims description 9
- 230000002411 adverse Effects 0.000 claims description 8
- 102220638992 Beta-enolase_H16D_mutation Human genes 0.000 claims description 7
- 102220581530 DNA dC->dU-editing enzyme APOBEC-3G_E67A_mutation Human genes 0.000 claims description 7
- 102220624881 PDZ and LIM domain protein 2_L80K_mutation Human genes 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 7
- 210000001616 monocyte Anatomy 0.000 claims description 7
- 102220242995 rs1555187010 Human genes 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 108700004922 F42A Proteins 0.000 claims description 6
- 102220515709 Interferon regulatory factor 8_R81K_mutation Human genes 0.000 claims description 6
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 claims description 6
- 102220349468 c.194C>T Human genes 0.000 claims description 6
- 102220353454 c.262A>G Human genes 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 102200080011 rs755832705 Human genes 0.000 claims description 6
- 102220497102 5-hydroxytryptamine receptor 3B_P65V_mutation Human genes 0.000 claims description 5
- 102220619065 Alpha-1,3-galactosyltransferase 2_R81E_mutation Human genes 0.000 claims description 5
- 102220624991 Bcl-2-like protein 2_H79N_mutation Human genes 0.000 claims description 5
- 102220597417 Fizzy-related protein homolog_R81L_mutation Human genes 0.000 claims description 5
- 102220571087 Growth arrest and DNA damage-inducible protein GADD45 gamma_L80E_mutation Human genes 0.000 claims description 5
- 101001127203 Homo sapiens 60S ribosomal protein L36a Proteins 0.000 claims description 5
- 102220524218 Interferon regulatory factor 6_N88H_mutation Human genes 0.000 claims description 5
- 102220511586 Kappa-casein_D84R_mutation Human genes 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- 102220602029 Neutrophil elastase_R81P_mutation Human genes 0.000 claims description 5
- 102220517304 Phosphate-regulating neutral endopeptidase PHEX_Y107L_mutation Human genes 0.000 claims description 5
- 102220550572 Proteasome maturation protein_L19E_mutation Human genes 0.000 claims description 5
- 102220547809 Serine/threonine-protein kinase B-raf_N88T_mutation Human genes 0.000 claims description 5
- 102220559239 Voltage-dependent L-type calcium channel subunit alpha-1C_L36A_mutation Human genes 0.000 claims description 5
- 102220370481 c.101C>G Human genes 0.000 claims description 5
- 102220420188 c.193C>A Human genes 0.000 claims description 5
- 102220427208 c.233T>C Human genes 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 239000012642 immune effector Substances 0.000 claims description 5
- 229940121354 immunomodulator Drugs 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 102220234844 rs1131690927 Human genes 0.000 claims description 5
- 102220110995 rs115116507 Human genes 0.000 claims description 5
- 102220266103 rs199901239 Human genes 0.000 claims description 5
- 102200158049 rs387906619 Human genes 0.000 claims description 5
- 102220062242 rs786201968 Human genes 0.000 claims description 5
- 102220098003 rs876661384 Human genes 0.000 claims description 5
- 230000001131 transforming effect Effects 0.000 claims description 5
- 102220504866 Aladin_L40S_mutation Human genes 0.000 claims description 4
- 102220465452 Angiogenin_K64Q_mutation Human genes 0.000 claims description 4
- 102220595179 Casein kinase II subunit alpha'-interacting protein_F78W_mutation Human genes 0.000 claims description 4
- 102220603939 Clathrin heavy chain 1_P65N_mutation Human genes 0.000 claims description 4
- 102220630764 Fibrinogen alpha chain_R38S_mutation Human genes 0.000 claims description 4
- 102220485773 Glycophorin-A_L94I_mutation Human genes 0.000 claims description 4
- 102220548801 Mitochondrial import inner membrane translocase subunit TIM16_L94A_mutation Human genes 0.000 claims description 4
- 102220529451 Phorbol-12-myristate-13-acetate-induced protein 1_L36E_mutation Human genes 0.000 claims description 4
- 102220552473 Platelet-activating factor acetylhydrolase_K64D_mutation Human genes 0.000 claims description 4
- 102220471703 Proteasome subunit alpha type-7_K32A_mutation Human genes 0.000 claims description 4
- 102220511395 Proteasome subunit beta type-10_K35T_mutation Human genes 0.000 claims description 4
- 102220519967 Protein DEK_L66A_mutation Human genes 0.000 claims description 4
- 102220471503 Replication factor C subunit 4_R38D_mutation Human genes 0.000 claims description 4
- 102220560185 Stromal cell-derived factor 1_K64R_mutation Human genes 0.000 claims description 4
- 102220500923 Telomerase reverse transcriptase_K35D_mutation Human genes 0.000 claims description 4
- 102220610852 Thialysine N-epsilon-acetyltransferase_L72G_mutation Human genes 0.000 claims description 4
- 102220559056 Voltage-dependent L-type calcium channel subunit alpha-1C_L36I_mutation Human genes 0.000 claims description 4
- 102220559240 Voltage-dependent L-type calcium channel subunit alpha-1C_P34S_mutation Human genes 0.000 claims description 4
- 102220345545 c.103A>C Human genes 0.000 claims description 4
- 102220431680 c.124T>G Human genes 0.000 claims description 4
- 102220350876 c.190A>G Human genes 0.000 claims description 4
- 102220359607 c.194C>A Human genes 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 102220004796 rs104893939 Human genes 0.000 claims description 4
- 102220197507 rs1057519494 Human genes 0.000 claims description 4
- 102220223535 rs1060501767 Human genes 0.000 claims description 4
- 102220223852 rs1060502978 Human genes 0.000 claims description 4
- 102220234588 rs1114167484 Human genes 0.000 claims description 4
- 102220234204 rs1114167734 Human genes 0.000 claims description 4
- 102200081185 rs121909273 Human genes 0.000 claims description 4
- 102200042537 rs121909608 Human genes 0.000 claims description 4
- 102200115315 rs121918084 Human genes 0.000 claims description 4
- 102220295568 rs1554341697 Human genes 0.000 claims description 4
- 102200066678 rs1554618767 Human genes 0.000 claims description 4
- 102220322294 rs1554831400 Human genes 0.000 claims description 4
- 102220039997 rs587778128 Human genes 0.000 claims description 4
- 102220056637 rs730880955 Human genes 0.000 claims description 4
- 102200073920 rs763623409 Human genes 0.000 claims description 4
- 102220097736 rs774586397 Human genes 0.000 claims description 4
- 102220097967 rs876660873 Human genes 0.000 claims description 4
- 102220638985 Beta-enolase_H16E_mutation Human genes 0.000 claims description 3
- 102220630762 Fibrinogen alpha chain_R38N_mutation Human genes 0.000 claims description 3
- 102220538345 Putative stereocilin-like protein_K35M_mutation Human genes 0.000 claims description 3
- 230000020411 cell activation Effects 0.000 claims description 3
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 claims description 3
- 102220320766 rs1554448978 Human genes 0.000 claims description 3
- 102220250393 rs553900705 Human genes 0.000 claims description 3
- 102220058220 rs730881937 Human genes 0.000 claims description 3
- 102200076864 rs869312138 Human genes 0.000 claims description 3
- 102220617354 Leucine-rich repeat-containing protein 34_V91W_mutation Human genes 0.000 claims description 2
- 102200023310 rs141703710 Human genes 0.000 claims description 2
- 108700025316 aldesleukin Proteins 0.000 abstract description 87
- 229940087463 proleukin Drugs 0.000 abstract description 78
- 230000028993 immune response Effects 0.000 abstract description 4
- 238000003259 recombinant expression Methods 0.000 abstract description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 220
- 108090000623 proteins and genes Proteins 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 45
- 239000000203 mixture Substances 0.000 description 38
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 37
- -1 IL- lβ Proteins 0.000 description 29
- 239000012636 effector Substances 0.000 description 28
- 238000001516 cell proliferation assay Methods 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 24
- 230000001225 therapeutic effect Effects 0.000 description 23
- 238000009472 formulation Methods 0.000 description 22
- 230000004083 survival effect Effects 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 230000006052 T cell proliferation Effects 0.000 description 18
- 230000037396 body weight Effects 0.000 description 18
- 230000035772 mutation Effects 0.000 description 18
- 230000004071 biological effect Effects 0.000 description 17
- 230000002269 spontaneous effect Effects 0.000 description 17
- 238000011740 C57BL/6 mouse Methods 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 230000009089 cytolysis Effects 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 15
- 230000003442 weekly effect Effects 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- 206010027476 Metastases Diseases 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- 238000002784 cytotoxicity assay Methods 0.000 description 12
- 231100000263 cytotoxicity test Toxicity 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 11
- 239000012228 culture supernatant Substances 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 230000009401 metastasis Effects 0.000 description 11
- 238000000134 MTT assay Methods 0.000 description 10
- 231100000002 MTT assay Toxicity 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 238000011729 BALB/c nude mouse Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 238000008157 ELISA kit Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 231100001274 therapeutic index Toxicity 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 229960005310 aldesleukin Drugs 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 230000007755 survival signaling Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000036757 core body temperature Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 5
- 241001227713 Chiron Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 206010027458 Metastases to lung Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 3
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 238000002737 cell proliferation kit Methods 0.000 description 3
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 102000057041 human TNF Human genes 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000002631 hypothermal effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 238000010845 search algorithm Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000440 toxicity profile Toxicity 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 208000031636 Body Temperature Changes Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000012766 Growth delay Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 241000701109 Human adenovirus 2 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000031641 Ideal Body Weight Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000037 Polyproline Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 description 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102220466046 U1 small nuclear ribonucleoprotein C_C25S_mutation Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000012707 chemical precursor Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 108010026466 polyproline Proteins 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000013643 reference control Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 102220572334 5-formyltetrahydrofolate cyclo-ligase_K9D_mutation Human genes 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 208000011776 Aggressive B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical group CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 206010021034 Hypometabolism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 102220592496 Non-homologous end-joining factor 1_Q11A_mutation Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 229920004896 Triton X-405 Polymers 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical class 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical class CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
Definitions
- the invention relates to muteins of human interleukin-2 (IL-2) having improved therapeutic efficacy. Also provided are methods for producing the novel molecules and pharmaceutical formulations that can be utilized to treat cancer and to stimulate the immune system of a mammal.
- IL-2 human interleukin-2
- Interleukin-2 is a potent stimulator of natural killer (NK) and T-cell proliferation and function (Morgan et al. (1976) Science 193:1007-1011).
- This naturally occurring lymphokine has been shown to have anti-tumor activity against a variety of malignancies either alone or when combined with lymphokine-activated killer (LAK) cells or tumor-infiltrating lymphocytes (TIL) (see, for example, Rosenberg et al. (1987) N. Engl J. Med. 316:889-897; Rosenberg (1988) Ann. Surg. 208:121-135; Topalian et al. (1988) J Clin. Oncol.
- IL-2-induced natural killer ( ⁇ K) cells trigger dose-limiting toxicities (OUT) as a consequence of overproduction of pro-inflammatory cytokines including IF ⁇ - ⁇ , IF ⁇ - ⁇ , T ⁇ F- ⁇ , T ⁇ F- ⁇ , IL-l ⁇ , and IL-6.
- cytokines include IF ⁇ - ⁇ , IF ⁇ - ⁇ , T ⁇ F- ⁇ , T ⁇ F- ⁇ , IL-l ⁇ , and IL-6.
- cytokines activate monocytes/macrophages and induce nitric oxide production leading to subsequent damage of endothelial cells (Dubinett et al. (1994) Cell Immunol. 157:170- 180; Samlowski et al. (1995) J Immunother. Emphasis Tumor Immunol. 18:166-178).
- IL-2R high affinity IL-2 receptor
- BAY50-4798 the N88R IL-2 mutein of mature human IL-2 disclosed in hitemational Publication No. WO 99/60128, and Shanafelt et al. (2000) Nat. Biotechnol. 18:1197- 202
- NK functions such as natural (NK), LAK, and ADCC cytolytic killing, cytokine production, and proliferation depend on the activation of specific intermediates in distinct NK intracellular signaling pathways.
- Proleukin® IL-2 (comprising the recombinant human IL-2 mutein aldesleukin; Chiron Corporation, Emeryville, California) has been approved by the FDA to treat melanoma and renal carcinoma, and is being studied for other clinical indications, including non-Hodgkin's lymphoma, HIV, and breast cancer.
- IL-2 muteins that have reduced toxicities and/or enhanced IL-2-mediated NK cell or T cell effector functions would have broader use and would be particularly advantageous for cancer therapy and for modulating the immune response.
- the invention relates to muteins of human interleukin-2 (IL-2) that have improved functional profiles predictive of reduced toxicities.
- the muteins induce a lower level of pro-inflammatory cytokine production by NK cells while maintaining or increasing NK cell proliferation, maintaining NK-mediated NK, LAK, and ADCC cytolytic functions, and maintain T cell proliferative function as compared to the des- alanyl-1, C125S human IL-2 or C125S human IL-2 muteins.
- Isolated nucleic acid molecules encoding muteins of human IL-2 and isolated polypeptides comprising these muteins are provided.
- the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a mutein of human IL-2.
- the nucleic acid molecule encodes a mutein of human IL-2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186
- the invention includes an isolated nucleic acid molecule encoding a mutein of human IL-2 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 17
- the invention includes an isolated nucleic acid molecule comprising a nucleotide sequence encoding a mutein of human IL-2, wherein the mutein has an amino acid sequence comprising residues 2-133 of a sequence selected from the group consisting of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164
- the invention includes an isolated nucleic acid molecule comprising a nucleotide sequence comprising nucleotides 4-399 of a sequence selected from the group consisting of SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 17
- the nucleic acid molecules described herein may further comprise a substitution, wherein nucleotides 373-375 of SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183,
- the nucleic acid molecules described herein may further comprise a substitution, wherein nucleotides 373-375 of SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183,
- nucleic acid molecules described herein are further modified to optimize expression.
- Such nucleic acids comprise a nucleotide sequence, wherein one or more codons encoding the mutein have been optimized for expression in a host cell of interest.
- Exemplary nucleic acids containing optimized codons may include, but are not limited to, a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:345, nucleotides 4-399 of SEQ ID NO:345, SEQ ID NO:346, and nucleotides 4-399 of SEQ ID NO:346.
- the present invention further includes an expression vector for use in selected host cells, wherein the expression vector comprises one or more of the nucleic acids of the present invention.
- the nucleic acid sequences are operably linked to control elements compatible with expression in the selected host cell.
- control elements include, but are not limited to, the following: transcription promoters, transcription enhancer elements, transcription termination signals, polyadenylation sequences, sequences for optimization of initiation of translation, and translation termination sequences.
- transcription promoters include, but are not limited to those derived from polyoma, Adenovirus 2, cytomegalovirus, and Simian Virus 40.
- the invention provides cells comprising the expression vectors of the present invention, wherein the nucleic acid sequence (e.g., encoding a mutein of human IL-2) is operably linked to control elements compatible with expression in the selected cell.
- the cells are mammalian cells.
- Exemplary mammalian cells include, but are not limited to, Chinese hamster ovary cells (CHO) or COS cells.
- compositions comprising any of the expression vectors and host cells of the present invention for recombinant production of the human IL-2 muteins.
- Such compositions may include a pharmaceutically acceptable carrier.
- the invention provides an isolated polypeptide comprising a mutein of human IL-2.
- the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172,
- the invention includes an isolated polypeptide comprising amino acid residues 2-133 of an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188,
- the polypeptides described herein may further comprise a substitution, wherein an alanine residue is substituted for the serine residue at position 125 of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182,
- the polypeptides described herein may further comprise a substitution, wherein a cysteine residue is substituted for the serine residue at position 125 of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182,
- the isolated polypeptide comprises the amino acid sequence of SEQ ID NO:4 with a serine substituted for cysteine at position 125 of SEQ ID NO:4 and at least one additional amino acid substitution within SEQ ID NO:4, wherein the mutein: 1) maintains or enhances proliferation of natural killer (NK) cells, and 2) induces a decreased level of pro-inflammatory cytokine production by NK cells; as compared with a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2.
- NK natural killer
- substitutions include, but are not limited to, T7A, T7D, T7R, K8L, K9A, K9D, K9R, K9S, K9V, K9W, T10K, T10N, QUA, Q11R, Q11T, E15A, H16D, H16E, L19D, L19E, D20E, I24L, K32A, K32W, N33E, P34E, P34R, P34S, P34T, P34V, K35D, K35I, K35L, K35M, K35N, K35P, K35Q, K35T, L36A, L36D, L36E, L36F, L36G, L36H, L36I, L36K, L36M, L36N, L36P, L36R, L36S, L36W, L36Y, R38D, R38G, R38N, R38P, R38S, L40D, L40G, L40N
- the polypeptides may further comprise a deletion of alanine at position 1 of SEQ ID NO:4.
- Increased proliferation of natural killer (NK) cells and decreased levels of pro- inflammatory cytokine production by NK cells can be detected using a NK-92 bioassay.
- the effects of the polypeptides described herein on proliferation of NK cells and pro- inflammatory cytokine production by NK cells are compared with the effects of a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable assay conditions.
- an NK-92 bioassay is used to show that the polypeptides described herein induce a decreased level of the pro-inflammatory cytokine TNF- ⁇ relative to that observed for a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable assay conditions.
- a NK3.3 cytotoxicity bioassay is used to show that the polypeptides described herein maintain or improve human NK cell-mediated natural killer cytotoxicity, lymphokine activated killer (LAK) cytotoxicity, or ADCC-mediated cytotoxicity relative to that observed for a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable assay conditions.
- the polypeptides described herein maintain or improve induction of phosphorylated AKT in the NK 3.3 cell line relative to that observed for a similar amount of des-alanyl 1 C125S human IL-2 or C125S human IL-2 under comparable assay conditions.
- the NK cell proliferation induced by the mutein is greater than 150% of that induced by a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable assay conditions.
- the NK cell proliferation induced by the mutein is greater than 170%, of that induced by des-alanyl-1, C125S human IL-2 or C125S human IL-2.
- the NK cell proliferation induced by the mutein is about
- the NK cell proliferation induced by said mutein is increased by at least 10% over that induced by a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable assay conditions. In certain embodiments, the NK cell proliferation induced by said mutein is increased by at least 15% over that induced by des-alanyl-1, C125S human IL-2 or C125S human IL-2.
- the pro-inflammatory cytokine production induced by said mutein is less than 100%o of that induced by a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 under similar assay conditions. In certain embodiments, the pro-inflammatory cytokine production induced by said mutein is less than 70%> of that induced by des-alanyl-1, C125S human IL-2 or C125S human IL-2.
- the invention provides an isolated polypeptide comprising a mutein of human IL-2, wherein the mutein comprises the amino acid sequence set forth in SEQ ID NO:4 with a serine substituted for cysteine at position 125 of SEQ ID NO:4 and at least one additional amino acid substitution within SEQ ID NO:4, wherein the ratio of IL-2-induced NK cell proliferation to ⁇ L-2-induced TNF- ⁇ production of said mutein is at least 1.5-fold greater than that observed for a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable assay conditions, wherein NK cell proliferation at 0.1 nM mutein and TNF- ⁇ production at 1.0 nM mutein are assayed using the NK-92 bioassay.
- the ratio is at least 2.5-fold greater than that observed for des-alanyl-1, C125S human IL-2 or C125S human IL-2. In other embodiments, the ratio is at least 3.0-fold greater than that observed for des-alanyl-1, C125S human IL-2 or C125S human IL-2.
- the invention provides an isolated polypeptide, wherein the mutein demonstrates improved tolerability when administered to a subject as determined by measurement of body temperature using an in vivo temperature chip, measurement of vascular leak, or measurement of maximum tolerated dose in the subject.
- the invention provides an isolated polypeptide comprising a mutein of human IL-2, wherein the mutein has a higher maximum tolerated dose relative to that observed for des-alanyl-1, C125S human IL-2 or C125S human IL-2, wherein said maximum tolerated dose is determined using a B16F10 melanoma animal model.
- the invention provides an isolated polypeptide comprising a mutein of human IL-2, wherein said mutein shows comparable or improved anti-tumor activity and reduced adverse effects compared to treatment with des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable treatment conditions, wherein said anti-tumor activity is evaluated using a B16F10 melanoma animal model.
- the invention provides an isolated polypeptide comprising a mutein of human IL-2, wherein said mutein shows comparable or improved anti-tumor activity and reduced adverse effects compared to treatment with des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable treatment conditions, wherein said anti-tumor activity is evaluated using a high grade non-Hodgkin's lymphoma Namalwa animal model or a low grade non-Hodgkin's lymphoma Daudi animal model.
- the invention provides an isolated polypeptide comprising a mutein of human IL-2, wherein said mutein when coadministered with rituximab shows comparable or improved anti-tumor activity and reduced adverse effects compared to treatment with des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable treatment conditions, wherein said anti-tumor activity is evaluated using a high grade non-Hodgkin's lymphoma Namalwa animal model or a low grade non-Hodgkin's lymphoma Daudi animal model.
- the invention provides an isolated polypeptide, wherein the mutein shows improved immune effector cell activation compared with a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2.
- Activated immune cells may include, but are not limited to, a T cell, a NK cell, a monocyte, a macrophage, and a neutrophil.
- the invention provides an isolated polypeptide, wherein the mutein shows improved antibody-dependent cellular cytotoxicity (ADCC)-mediated cytolytic killing compared with a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2.
- ADCC antibody-dependent cellular cytotoxicity
- the invention provides an isolated polypeptide, wherein the mutein causes less vascular leak as compared with a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 in an animal model of vascular leak syndrome. In certain embodiments, the invention provides an isolated polypeptide, wherein the mutein causes less change in body temperature as compared with a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 in an animal model, wherein body temperature is monitored in the animal with a temperature chip.
- the invention includes an isolated polypeptide comprising an amino acid sequence for a mutein of human IL-2, wherein the mutein comprises the amino acid sequence set forth in SEQ ID NO:4 with a serine substituted for cysteine at position 125 of SEQ ID NO:4 and with at least one additional amino acid substitution at a position of SEQ ID NO:4 selected from the group consisting of positions 16, 36, 40, 42, 61, 65, 67, 72, 91, 94, 95, and 107.
- the polypeptide further comprises a deletion of alanine at position 1 of SEQ ID NO:4.
- the invention provides a method of producing a mutein of human interleukin-2 (IL-2) comprising transforming a host cell with an expression vector comprising any of the nucleic acid molecules described herein and culturing the host cell in a cell culture medium under conditions that allow expression of the nucleic acid molecule as a polypeptide, and isolating the polypeptide.
- IL-2 human interleukin-2
- the mutein of human interleukin-2 is capable of maintaining or enhancing proliferation of NK cells and also induces a lower level of pro-inflammatory cytokine production by NK cells as compared with a similar amount of a reference human IL-2 mutein selected from des-alanyl-1, C125S human LL-2 and C125 human IL-2, wherein NK cell proliferation and pro-inflammatory cytokine production are assayed under similar assay conditions using the NK-92 bioassay.
- the invention provides compositions comprising a therapeutically effective amount of one or more of the polypeptides described herein comprising a mutein of human IL-2. Such compositions may further include a pharmaceutically acceptable carrier.
- the invention provides a method for stimulating the immune system of a mammal.
- the method comprises administering to a mammal a therapeutically effective amount of a human IL-2 mutein that induces a lower level of pro-inflammatory cytokine production by NK cells and maintains or enhances NK cell proliferation compared to a similar amount of a reference IL-2 molecule selected from des-alanyl-1, C125S human IL-2 and C125S human IL-2, wherein NK cell proliferation and pro-inflammatory cytokine production are assayed under comparable assay conditions using the NK-92 bioassay.
- the mammal is a human.
- the human IL-2 mutein used to stimulate the immune system comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172 174, 176, 178, 180, 182, 184, 186, 188, 190,
- the human IL-2 mutein used to stimulate the immune system comprises an amino acid sequence comprising residues 2-133 of an amino acid sequence selected from the group consisting of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 18
- the human IL-2 mutein used to stimulate the immune system may further comprise a substitution, wherein an alanine residue is substituted for the serine residue at position 125 of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178
- the human IL-2 mutein used to stimulate the immune system may further comprise a substitution, wherein a cysteine residue is substituted for the serine residue at position 125 of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178
- the invention provides a method for treating a cancer in a mammal, comprising administering to said mammal a therapeutically effective amount of a human IL-2 mutein, wherein said mutein induces a lower level of pro-inflammatory cytokine production by NK cells and maintains or enhances NK cell proliferation compared to a similar concentration of a reference IL-2 molecule selected from des- alanyl-1, C125S human IL-2 and C125S human IL-2 under similar assay conditions, wherein said NK cell proliferation and said pro-inflammatory cytokine production are assayed using the NK-92 bioassay.
- the mammal is a human.
- the human IL-2 mutein used for treating a cancer may comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176 178, 180, 182, 184, 186, 188, 190, 192
- the human IL-2 mutein used for treating a cancer may comprise an amino acid sequence comprising residues 2-133 of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 180, 182, 184, 186, 188, 190
- the human IL-2 mutein used for treating a cancer may further comprise a substitution, wherein an alanine residue is substituted for the serine residue at position 125 of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178
- the human IL-2 mutein used for treating a cancer may further comprise a substitution, wherein a cysteine residue is substituted for the serine residue at position 125 of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176,
- the method of treatment comprises administering IL-2 as an IL-2 mutein.
- the IL-2 mutein used in treatment comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164
- the IL-2 mutein used in treatment comprises residues 2- 133 of an amino acid sequence selected from the group consisting of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188
- the IL-2 mutein used in treatment further comprises a substitution, wherein a cysteine residue is substituted for the serine residue at position 125 of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128,
- Figure 1 outlines the schematic for compilation of the combination proliferation/pro-inflammatory cytokine production assay procedure used with IL-2 mutein-stimulated human PBMC isolated from normal human donors.
- Figure 2 shows proliferation and TNF- ⁇ production mediated by F42E IL-2 mutein in human PBMC.
- Figure 3 shows proliferation and TNF- ⁇ production mediated by L94Y IL-2 mutein in human PBMC.
- Figure 4 shows proliferation and TNF- ⁇ production mediated by E95D IL-2 mutein in human PBMC.
- Figure 5 shows proliferation and TNF- ⁇ production mediated by E95G IL-2 mutein in human PBMC.
- Figure 6 shows proliferation and TNF- ⁇ production mediated by Y107R IL-2 mutein in human PBMC.
- Figure 7 shows maintenance of human NK-mediated LAK and ADCC activity for IL-2 mutein-stimulated human PBMC isolated from normal human donors.
- Figure 8 shows a bar graph comparing the efficacies of Proleukin®, L2-7001®, RL-2, and IL-2 muteins, E95D and Y107R, administered thrice weekly in the B16F10 melanoma lung metastasis model in C57BL/6 mice, as described in Example 11.
- Figure 9 compares mean body weights of mice treated with Proleukin®, L2- 7001®, RL-2, or IL-2 muteins, E95D and Y107R, dosed thrice weekly in the B16F10 melanoma lung metastasis model in C57BL/6 mice, as described in Example 11.
- Figure 10 shows a bar graph comparing the efficacies of Proleukin®, L2-7001®,
- FIG. 11 compares mean body weights of mice treated with Proleukin®, L2- 7001®, RL-2, or IL-2 muteins, E95D and Y107R, dosed according to the "Sleijfer” protocol (5 days on/2 days off/5 days on) in the B16F10 melanoma lung metastasis model in C57BL/6 mice, as described in Example 11.
- Figure 12 shows a bar graph comparing the efficacies of Proleukin®, L2-7001®, RL-2, and IL-2 muteins, F42E and Y107R, administered according to the "Sleijfer" protocol (5 days on/2 days off/5 days on) in the B16F10 melanoma lung metastasis model in C57BL/6 mice, in repeat study as described in Example 11.
- Figure 13 compares mean body weights of mice treated with Proleukin®, L2- 7001®, RL-2, or IL-2 muteins, F42E and Y107R, dosed according to the "Sleijfer" protocol (5 days on 2 days off/5 days on) in the B16F10 melanoma lung metastasis model in C57BL/6 mice, in repeat study as described in Example 11.
- Figure 14 compares efficacies of Proleukin® and L2-7001®, dosed thrice weekly in the aggressive human Non-Hodgkin's Lymphoma model (Namalwa) in irradiated Balb/c nude mice, as described in Example 12.
- Figure 14 shows a plot of the mean tumor volume (mm 3 ) versus time (days post staging).
- Figure 15 compares efficacies of Proleukin®, L2-7001®, and the Y107R IL-2 mutein dosed thrice weekly in the aggressive human Non-Hodgkin's Lymphoma model (Namalwa) in irradiated Balb/c nude mice, as described in Example 12.
- Figure 15 sh ws a plot of the mean tumor volume (mm 3 ) versus time (days post staging).
- Figure 16 compares efficacies of Proleukin®, L2-7001®, and the E95D IL-2 mutein dosed thrice weekly in the aggressive human Non-Hodgkin's Lymphoma model (Namalwa) in irradiated Balb/c nude mice, as described in Example 12.
- Figure 16 shows a plot of the mean tumor volume (mm 3 ) versus time (days post staging).
- Figure 17 compares efficacies of single agent therapy with Proleukin®, L2- 7001®, and the Y107R IL-2 mutein dosed thrice weekly in the low grade Daudi human B-cell Non-Hodgkin's Lymphoma model in irradiated Balb/c nude mice, as described in Example 12.
- Figure 17 shows a plot of the mean tumor volume (mm 3 ) versus time (days post staging) and a summary of statistical results: %> tumor growth inhibition (TGI), partial response/complete response (PR/CR), P value, % body weight (BW) change, and clinical observations.
- Figure 18 compares efficacies of Proleukin® , L2-7001 ® , and the Y 107R IL-2 mutein administered in combination with rituximab thrice weekly in the low grade Daudi human B-cell Non-Hodgkin's Lymphoma model in irradiated Balb/c nude mice, as described in Example 12.
- Figure 18 shows a plot of the mean tumor volume (mm 3 ) versus time (days post staging) and a summary of statistical results: % tumor growth inhibition (TGI), partial response/complete response (PR/CR), P value, % body weight (BW) change, and clinical observations.
- Figure 19 compares levels of conditional survival and tumor growth inhibition for mice treated with Proleukin®, L2-7001®, or the Y107R IL-2 mutein in combination with rituximab thrice weekly in the low grade Daudi human B-cell Non-Hodgkin's Lymphoma model in irradiated Balb/c nude mice, as described in Example 12.
- Figure 19 shows a plot of the conditional survival (%>) versus tumor growth delay time (days for tumor progression to 1000 mm 3 ) and a table summarizing complete response (CR) statistics.
- Figure 20 compares mean body weights of mice treated with Proleukin®, L2- 7001®, or the Y107R IL-2 mutein in the presence or absence of rituximab, dosed thrice weekly in the low grade Daudi human B-cell Non-Hodgkin's Lymphoma model in irradiated Balb/c nude mice, as described in Example 12.
- Figure 21 shows a bar graph comparing drug tolerability of Proleukin®, L2- 7001®, and the IL-2 muteins, E95D and Y107R, as evaluated in an experimental acute IL-2-induced vascular leak syndrome model in C57B1/6 mice. 125 I-albumin retention in the lungs of mice, resulting from increased vascular leak caused by treatment with IL-2, was measured as described in Example 13.
- Figure 22 shows a plot depicting the changes in core body temperature of mice in response to treatment with IL-2.
- Proleukin® and L2-7001® were administered according to the "Sleijfer" protocol (5 days on 2 days off/5 days on) to C57BL/6 mice implanted subcutaneously with a temperature chip to monitor temperature after dosing with IL-2.
- FIG. 23 shows a plot comparing the core body temperatures of C57BL/6 mice treated with Proleukin®, L2-7001®, or an IL-2 mutein, L94Y, F42E, or E95G.
- Figure 24 shows a bar graph comparing the core body temperatures of C57BL/6 mice on day 5 at 4 hours post dosing with Proleukin®, L2-7001®, or an IL-2 mutein, E95D, L94Y, Yl 07R, or F42E.
- IL-2 was administered according to the "Sleijfer" protocol (5 days on/2 days off/5 days on) to C57BL/6 mice implanted subcutaneously with a temperature chip, as described in Example 14.
- Figure 25 shows the correlation between body temperature decreases and TNF- ⁇ plasma levels in C57BL/6 mice treated with Proleukin®, L2-7001®, or an IL-2 mutein, E95D, L94Y, Y107R, or F42E.
- pro- inflammatory cytokine is intended a cytokine that is able to stimulate the immune system.
- cytokines include, but are not limited to, IFN- ⁇ , IFN- ⁇ , TNF- ⁇ , TNF- ⁇ , IL- l ⁇ , and IL-6.
- mutein refers to a protein comprising a mutant amino acid sequence that differs from the amino acid sequence for the naturally occurring protein by amino acid deletions, substitutions, or both.
- the human IL-2 muteins of the present invention comprise an amino acid sequence that differs from the mature human IL-2 sequence by having a serine residue substituted for the cysteine residue at position 125 of the mature human IL-2 sequence (i.e., C125S) and at least one other amino acid substitution, and may further comprise one or more amino acid deletions relative to the mature human IL-2 sequence, such as deletion of the N-terminal alanine (Ala) at position 1 of the mature human IL-2 protein.
- Ala N-terminal alanine
- the human IL-2 muteins of the present invention retain the cysteine residue at position 125 of the mature human IL-2 sequence but have at least one other amino acid substitution, and may further comprise one or more amino acid deletions relative to the mature human IL-2 seuqence, such as deletion of the N-terminal alanin (Ala) at position 1 of the mature human IL-2 protein.
- These human IL- 2 muteins can be glycosylated or unglycosylated depending upon the host expression system used in their production.
- the particular substitutions disclosed herein result in a human IL-2 variant that retains the desired activities of eliciting reduced pro- inflammatory cytokine production while maintaining or increasing NK cell proliferation, as compared to the des-alanyl-1, C125S human IL-2 mutein or the C125S human IL-2 mutein using the NK-92 cell assays described herein. Having identified the positions within the human IL-2 sequence and the relevant substitutions at these positions that result in an IL-2 variant with reduced toxicity and/or improved NK cell proliferation, it is within the skill of one in the art to vary other residues within the human IL-2 sequence to obtain variants of the human IL-2 muteins disclosed herein that also retain these desired activities.
- Human IL-2 is initially translated as a precursor polypeptide, shown in SEQ ID NO:2, which is encoded by a nucleotide sequence such as that set forth in SEQ ID NO:l.
- the precursor polypeptide includes a signal sequence at residues 1-20 of SEQ ID NO:2.
- mature human IL-2 refers to the amino acid sequence set forth as SEQ ID NO:4, which is encoded by a nucleotide sequence such as that set forth as SEQ ID NO:3.
- C125S human IL-2 mutein or “C125S human IL-2” refer to a mutein of mature human IL-2 that retains the N-terminal alanine residing at position 1 of the mature human IL-2 sequence and which has a substitution of serine for cysteine at position 125 of the mature human IL-2 sequence.
- C125S human IL-2 mutein has the amino acid sequence set forth in SEQ ID NO: 6, which is encoded by a nucleotide sequence such as that set forth as SEQ ID NO:5.
- de-alanyl-1, C125S human IL-2 and “des- alanyl-1, serine- 125 human IL-2” refer to a mutein of mature human IL-2 that has a substitution of serine for cysteine at amino acid position 125 of the mature human IL-2 sequence and which lacks the N-terminal alanine that resides at position 1 of the mature human IL-2 sequence (i.e., at position 1 of SEQ ID NO:4).
- Des-alanyl-1, C125S human IL-2 has the amino acid sequence set forth in SEQ ID NO: 8, which is encoded by a nucleotide sequence such as that set forth in SEQ ID NO:7.
- aldesleukin coli recombinantly produced des-alanyl-1, C125S human IL-2 mutein, which is referred to as "aldesleukin,” is available commercially as a formulation that is marketed under the tradename Proleukin® IL-2 (Chiron Corporation, Emeryville, California).
- Proleukin® IL-2 Choiron Corporation, Emeryville, California.
- the des-alanyl-1, C125S human IL-2 and C125S human IL-2 muteins serve as reference IL-2 muteins for determining the desirable activities that are to be exhibited by the human IL-2 muteins of the invention.
- the desired activity of reduced IL-2-induced pro-inflammatory cytokine production, particularly TNF- ⁇ production, by NK cells in a suitable human IL-2 mutein of the invention is measured relative to the amount of pro-inflammatory cytokine production of NK cells that is induced by an equivalent amount of the des-alanyl-1, C125S human IL-2 mutein or C125S human IL-2 mutein under similar assay conditions.
- the desired activity of maintaining or increasing IL-2-induced NK cell proliferation in a suitable human IL-2 mutein of the invention is measured relative to the amount of NK cell proliferation induced by an equivalent amount of the des-alanyl-1, C125S human IL-2 or C125S human IL-2 mutein under similar assay conditions.
- Isolated nucleic acid molecules encoding human IL-2 muteins, and biologically active variants thereof, comprising the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution and which induce a lower level of pro-inflammatory cytokine production by NK cells while maintaining or increasing NK cell proliferation, as compared to these two reference IL-2 muteins are provided.
- the isolated polypeptides encoded by the nucleic acid molecules of the invention are also provided.
- Human IL-2 muteins of the invention include the muteins set forth in SEQ ID NOS:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196
- the muteins set forth in these foregoing amino acid sequences comprise the C125S human IL-2 amino acid sequence with one of the additional substitutions shown in Table 1 below.
- the human IL-2 muteins of the present invention have the initial alanine residue at position 1 of these amino acid sequences deleted, and thus comprise the des-alanyl-1, C125S human IL-2 amino acid sequence with one of the additional substitutions shown in Table 1 below.
- muteins thus have an amino acid sequence that comprises residues 2-133 of the sequence set forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104,
- the present invention also provides any nucleotide sequences encoding these muteins, for example, the coding sequences set forth in nucleotides 4-399 of the sequence set forth in SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105,
- Biologically active variants of the human IL-2 muteins of the invention including fragments and truncated fo ⁇ ns thereof, that have the desired human IL-2 mutein functional profile as noted herein are also provided.
- fragments or truncated forms of the disclosed human IL-2 muteins may be generated by removing amino acid residues from the full-length human IL-2 mutein amino acid sequence using recombinant DNA teclmiques well known in the art and described elsewhere herein.
- Suitable variants of the human IL-2 muteins of the invention will have biological activities similar to those exhibited by the novel human IL-2 muteins themselves, i.e., they have a low toxicity of the novel human IL-2 mutein (i.e., low or reduced pro-inflammatory cytokine production), as well as the ability to maintain or increase NK cell proliferation, when compared to the reference IL-2 molecule, i.e., des-alanyl-1, C125S or C125S human IL- 2, using the bioassays disclosed elsewhere herein.
- the reference IL-2 molecule i.e., des-alanyl-1, C125S or C125S human IL- 2
- any given novel human IL-2 mutein identified herein may have a different absolute level of a particular biological activity relative to that observed for the novel human IL-2 mutein of the invention, so long as it retains the desired biological profile of having reduced toxicity, that is, it induces a lower level of pro-inflammatory cytokine production by NK cells, and/or increased NK cell proliferation when compared to the reference human IL-2 mutein.
- Examples of human IL-2 muteins of the invention that comprise the amino acid sequence of C125S human IL-2 (SEQ ID NO:6) or des-alanyl-1, C125S human IL-2 (SEQ ID NO: 8) with at least one other substitution selected from the group shown below.
- Methods for producing muteins of human IL-2 that induce a lower level of pro- inflammatory production by NK cells and which maintain or increase NK cell proliferation relative to that observed for the reference IL-2 muteins are encompassed by the present invention. These methods comprise transforming a host cell with an expression vector comprising a nucleic acid molecule encoding a novel human IL-2 mutein of the invention, or encoding a biologically active variant thereof, culturing the host cell in a cell culture medium under conditions that allow expression of the encoded polypeptide, and isolating the polypeptide product.
- Methods are also provided for stimulating the immune system of an animal, or for treating a cancer in a mammal, comprising administering to the animal a therapeutically effective amount of a human IL-2 mutein of the invention, or biologically active variant thereof, wherein the IL-2 mutein or variant thereof induces a lower level of pro- inflammatory cytokine production by NK cells, and maintains or increases NK cell proliferation compared to des-alanyl-1, C125S human IL-2 or C125S human IL-2 as determined using the bioassays disclosed herein below.
- the present invention also provides a method for reducing interleukin-2 (IL-2)- induced toxicity symptoms in a subject undergoing IL-2 administration as a treatment protocol.
- IL-2 interleukin-2
- the method comprises administering an IL-2 mutein of the present invention, i.e., a mutein that induces a lower level of pro-inflammatory cytokine production by NK cells, and which maintains or increases NK cell proliferation compared to des-alanyl-1, C125S human IL-2 or C125S human IL-2 as determined using the bioassays disclosed herein below.
- an IL-2 mutein of the present invention i.e., a mutein that induces a lower level of pro-inflammatory cytokine production by NK cells, and which maintains or increases NK cell proliferation compared to des-alanyl-1, C125S human IL-2 or C125S human IL-2 as determined using the bioassays disclosed herein below.
- nucleic acid molecule is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
- the nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
- the invention encompasses isolated or substantially purified nucleic acid or protein compositions.
- An "isolated” or “purified” nucleic acid molecule or protein, or biologically active portion thereof, is substantially or essentially free from components that normally accompany or interact with the nucleic acid molecule or protein as found in its naturally occurring environment.
- an isolated or purified nucleic acid molecule or protein is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
- an "isolated" nucleic acid is free of sequences (preferably protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.
- the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived.
- a protein that is substantially free of cellular material includes preparations of protein having less than about 30%o, 20%, 10%>, 5%, or 1% (by dry weight) of contaminating protein.
- culture medium represents less than about 30%, 20%), 10%o, 5%o, or 1%) (by dry weight) of chemical precursors or non-protein-of-interest chemicals.
- novel human IL-2 muteins of the present invention have an increased therapeutic index compared to the des-alanyl-1, C125S human IL-2 mutein, or compared to the C 125 S human IL-2 mutein.
- the latter two muteins are referred to herein as "reference IL-2 muteins," as the biological profiles of the novel muteins of the invention are compared to the biological profiles of these two previously characterized muteins, where any given comparison is made using similar protein concentrations and comparable assay conditions, in order to classify the muteins of the present invention.
- the increased therapeutic index of the muteins of the present invention is reflected in an improved toxicity profile (i.e., the mutein induces a lower level of pro-inflammatory cytokine production by NK cells), an increased NK and/or T cell effector function without increased toxicity, or both an improved toxicity profile and an increased NK and/or T cell effector function of these muteins when compared to the toxicity profile and NK and/or T cell effector function of either of these two reference IL-2 muteins.
- an improved toxicity profile i.e., the mutein induces a lower level of pro-inflammatory cytokine production by NK cells
- an increased NK and/or T cell effector function without increased toxicity or both an improved toxicity profile and an increased NK and/or T cell effector function of these muteins when compared to the toxicity profile and NK and/or T cell effector function of either of these two reference IL-2 muteins.
- Three functional endpoints were used to select the muteins with increased therapeutic index: (1) the ability to reduce IL-2-induced pro-inflammatory cytokine production by NK cells as compared to des-alanyl-1, C125S human IL-2 or C125S human IL-2; (2) the ability to maintain or increase IL-2-induced proliferation of NK and T cells without an increase in pro-inflammatory cytokine production by the NK cells as compared to des-alanyl-1, C125S human IL-2 or C125S human IL-2; and (3) the ability to maintain or improve (i.e., increase) NK-mediated cytolytic cell killing as compared to des-alanyl-1, C125S human IL-2 or C125S human IL-2.
- NK-mediated cytolytic cell killing includes NK-mediated, lymphokine activated killer (LAK)-mediated, and antibody-dependent cellular cytotoxicity (ADCC)-mediated cytolytic killing.
- LAK lymphokine activated killer
- ADCC antibody-dependent cellular cytotoxicity
- the novel human IL-2 muteins disclosed herein that exhibit the greatest improvements in therapeutic index fall within three functional classes predictive of improved clinical benefit. Of note is that all of these muteins exhibit maintained or increased T cell proliferation activity and NK-mediated cytolytic activity.
- the first functional class of muteins is characterized by having beneficial mutations that reduce IL-2-induced pro-inflammatory cytokine production by NK cells as compared to a reference IL-2 mutein, i.e., des-alanyl-1, C125S human IL-2 or C125S human IL-2, while maintaining IL-2 -induced NK cell proliferation.
- the second functional class of muteins increases IL-2-induced NK cell proliferation relative to that induced by either of the reference IL-2 muteins, without negatively impacting (i.e., increasing) pro-inflammatory cytokine production relative to that induced by either of the reference IL-2 muteins.
- the third functional class of muteins includes muteins that are "bi-functional" in that they are able to reduce IL-2-induced pro-inflammatory cytokine production by NK cells while increasing IL-2-induced NK cell proliferation when compared to the levels of these activities induced by either of these two reference IL-2 muteins.
- Assays to measure IL-2-induced NK cell proliferation and pro-inflammatory cytokine production by freshly isolated NK cells are well known in the art. See, for example, Perussia (1996) Methods 9:370 and Baume et al. (1992) Eur. J. Immunol. 22:1- 6.
- the NK-92 cell line has phenotypic and functional characteristics of NK cells, including proliferation in the presence of IL-2 (Gong et al. (1994) Leukemia 8:652), however little or no production of TNF- ⁇ in the presence of IL-2 has previously been reported (Nagashima et al. (1998) Blood 91 :3850).
- IL-2 bioassays that have been developed for screening functional activities of human NK and T cells are disclosed herein and in the Experimental section below.
- IL-2 bioassays disclosed herein are used to screen IL-2 muteins of interest to determine whether they retain the desired characteristics of the muteins disclosed herein. Of particular interest is their decreased induction of TNF- ⁇ production by NK cells.
- IL-2-induced NK cell proliferation and TNF- ⁇ production are measured using the IL-2 bioassay described herein below for the human NK-92 cell line (ATCC CRL-2407, CMCC ID #11925).
- NK-92 cell line see Gong et al.
- NK-92 bioassay 194200 IL-2 muteins of the invention induce a level of pro-inflammatory cytokine production by NK cells that is decreased relative to that induced by the reference IL-2 muteins, i.e., des-alanyl-1, C125S human IL-2 or C125S human IL-2 mutein, particularly with respect to induction of TNF- ⁇ production by NK cells.
- the human IL-2 muteins of the present invention induce a minimal level of TNF- ⁇ production by NK cells that is at least 20%> of that induced by a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable assay conditions
- the maximal level of TNF- ⁇ production by NK cells that can be induced by a mutein of the present invention depends upon the functional class into which a mutein has been categorized.
- the muteins have been selected for greatly enhanced induction of NK cell proliferation without having a negative impact on IL-2-induced TNF- ⁇ production by NK cells (i.e., the second functional class of muteins).
- the human IL-2 muteins of the present invention induce a level of TNF- ⁇ production by NK cells that is similar to (i.e., ⁇ 10%>) that induced by the reference IL-2 muteins or, preferably, less than 90%> of that induced by the reference IL-2 muteins, where TNF- ⁇ production is assayed using the human NK-92 cell line (ATCC CRL-2407, CMCC ID #11925) (i.e., using the NK-92 bioassay disclosed herein) and a 1.0 nM or 100 pM (i.e., 0.1 nM) concentration of the respective human IL-2 muteins.
- TNF- ⁇ production is assayed using the human NK-92 cell line (ATCC CRL-2407, CMCC ID #11925) (i.e., using the NK-92 bioassay disclosed herein) and a 1.0 nM or 100 pM (i.e., 0.1 nM) concentration
- the human IL-2 muteins of the present invention induce a level of TNF- ⁇ production by NK cells that is less than 90%), preferably less than 85%, even more preferably less than 80%> of the TNF- ⁇ production induced by a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable assay conditions, where TNF- ⁇ production is assayed using the human NK-92 cell line (i.e., using the NK-92 bioassay disclosed herein) and a 1.0 nM concentration of the respective human IL-2 muteins.
- the human IL-2 muteins of the invention induce at least 20%> but less than 60%> of the TNF- ⁇ production induced by des-alanyl-1, C125S human IL-2 or C125S human IL-2, where TNF- ⁇ production is assayed using the human NK-92 cell line (i.e., using the NK-92 bioassay disclosed herein) and a 1.0 nM concentration of the respective human IL-2 muteins.
- Such muteins which also maintain or increase IL-2-induced NK cell proliferation relative to the reference IL-2 muteins, fall within the first functional class of IL-2 muteins.
- the human IL-2 muteins of the present invention induce at least 70%>, preferably at least 75%, more preferably at least 80%>, and most preferably at least 85% and up to and including 100%> (i.e., equivalent values) of the desired biological activity relative to the level of activity observed for a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 under comparable assay conditions.
- suitable IL-2 muteins of the invention induce a level of NK cell proliferation that is at least 70%o, preferably at least 75%, more preferably at least 80%>, and most preferably at least 85%>, 90%>, 95%> and up to and including 100%> ( ⁇ 5%>) of the NK cell proliferation activity induced by a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2, where NK cell proliferation is assayed under comparable conditions using the same bioassay (i.e., the NK-92 bioassay disclosed herein) and similar amounts of these IL-2 muteins.
- suitable IL-2 muteins of the invention induce a level of NK cell proliferation that is at least 105%, 110%, 115%, more preferably at least 120%,, even more preferably at least 125%, and most preferably at least 130%, 140%, or 150% of the NK cell proliferation activity observed for a similar amount of des-alanyl-1, C125S human IL-2 or C125S human IL-2 using the same NK cell proliferation assay (for example, the NK-92 bioassay disclosed herein).
- Assays to measure NK cell proliferation are well known in the art (see, for example, Baume et al. (1992) Eur. J. Immuno.
- NK-92 cells are used to measure IL-2-induced pro-inflammatory cytokine production, particularly TNF- ⁇ production, and NK cell proliferation (i.e., the NK-92 bioassay disclosed herein).
- Suitable concentrations of human IL-2 mutein for use in the NK cell proliferation assay include about 0.005 nM (5 pM) to about 1.0 nM (1000 pM), including 0.005 nM, 0.02 nM, 0.05 nM, 0.1 nM, 0.5 nM, 1.0 nM, and other such values between about 0.005 nM and about 1.0 nM.
- the NK cell proliferation assay is carried out using NK-92 cells and a concentration of human IL-2 mutein of about 0.1 nM or about 1.0 nM.
- the human IL-2 muteins of the present invention have a more favorable ratio of IL-2-induced NK cell proliferation:IL-2-induced pro-inflammatory cytokine production by NK cells than does either des-alanyl-1, C125S human IL-2 or C125S human IL-2, where these activities are measured for each mutein using comparable protein concentrations and bioassay conditions.
- suitable human IL-2 muteins of the invention have a ratio of IL-2-induced NK cell proliferation at 0.1 nM mutein:IL-2 -induced TNF- ⁇ production by NK cells at 1.0 nM mutein that is at least 1.5-fold that obtained with des-alanyl-1, C125S human IL-2 or C125S human IL-2 under similar bioassay conditions and protein concentrations, more preferably at least 1.75-fold, 2.0-fold, 2.25-fold, even more preferably at least 2.75-fold, 3.0-fold, or 3.25- fold that obtained with the reference IL-2 muteins.
- the human IL- 2 muteins of the invention have a ratio of IL-2 -induced NK cell proliferation at 0.1 nM mutein: IL-2-induced TNF- ⁇ production by NK cells at 1.0 nM mutein that is at least 3.5- fold, 4.0-fold, 4.5-fold, or even 5.0-fold that obtained with des-alanyl-1 human IL-2 or C125S human IL-2 mutein under similar bioassay conditions and protein concentrations.
- the muteins of the present invention may also enhance (i.e., increase) NK cell survival relative to that observed with des-alanyl-1, C125S human IL-2 or C125S human IL-2 under similar bioassay conditions and protein concentrations.
- NK cell survival can be determined using any known assay in the art, including the assays described herein.
- NK cell survival in the presence of an IL-2 mutein of interest can be determined by measuring the ability of the IL-2 mutein to block glucocorticosteroid programmed cell death and induce BCL-2 expression in NK cells (see, for example, Armant et al. (1995) Immunology 85:331).
- the present invention provides an assay for monitoring IL-2 effects on NK cell survival.
- NK cell survival in the presence of a human IL-2 mutein of interest is determined by measuring the ability of the mutein to induce the cell survival signaling cascade in NK 3.3 cells (CMCC ID#12022; see Kornbluth (1982) J Immunol 129(6):2831-2837) using a pAKT ELISA. In this manner, upregulation of a human IL-2 mutein of interest
- AKT phosphorylation in NK cells by an IL-2 mutein of interest is used as an indicator of NK cell survival.
- the IL-2 muteins for use in the methods of the present invention will activate and/or expand natural killer (NK) cells to mediate lymphokine activated killer (LAK) activity and antibody-dependent cellular cytotoxicity (ADCC). Resting (unactivated) NK cells mediate spontaneous or natural cytotoxicity against certain cell targets referred to as "NK-cell sensitive" targets, such as the human erythroleukemia K562 cell line. Following activation by IL-2, NK cells acquire LAK activity.
- LAK activity can be assayed, for example, by measuring the ability of IL-2-activated NK cells to kill a broad variety of tumor cells and other "NK-insensitive" targets, such as the Daudi B-cell lymphoma line, that are normally resistant to lysis by resting (i.e., unactivated) NK cells.
- ADCC activity can be assayed by measuring the ability of IL-2-activated NK cells to lyse "LAK-sensitive/NK-insensitive" target cells, such as Daudi B-cell lymphoma line, or other target cells not readily lysed by resting (i.e., unactivated) NK cells in the presence of optimal concentrations of relevant tumor cell specific antibodies.
- the ADCC activity of the IL-2 muteins of the invention is measured using the NK3.3 cell line, which displays phenotypic and functional characteristics of peripheral blood NK cells.
- this assay is referred to herein as the "NK3.3 cytotoxicity bioassay.”
- the human IL-2 muteins of the invention may also maintain or enhance IL-2- induced T cell proliferation compared to that observed for des-alanyl-1, C125S human IL-2 or C125S human IL-2 under similar bioassay conditions and protein concentrations.
- T cell proliferation assays are well known in the art.
- the human T- cell line Kit225 (CMCC ID#11234; Hori et al. (1987) Blood 70(4): 1069- 1072) is used to measure T cell proliferation in accordance with the assay described herein below.
- the leading human IL-2 mutein candidates identified herein fall within three functional classes.
- the first functional class includes those muteins that induce a lower level of TNF- ⁇ production by NK cells, about 60%>, or less, of that induced by des-alanyl- 1, C125S human IL-2 or C125S human IL-2, when all muteins are assayed under similar conditions at a protein concentration of 1.0 nM, and which maintain or enhance NK cell proliferation relative to des-alanyl-1, C125S human IL-2 or C125S human IL-2.
- muteins can be further subdivided into two subclasses: (1) those human IL-2 muteins that enhance (i.e., greater than 100%,) IL-2-induced NK cell proliferation relative to that observed for the reference human IL-2 muteins when these muteins are assayed under similar conditions at a protein concentration of about 1.0 nM, but which have reduced (i.e., less than 100%,) NK cell proliferative activity relative to that observed for the reference human IL-2 muteins at concentrations of about 0.1 nM or below; and (2) those human IL-2 muteins that enhance (i.e., greater than 100%,) or maintain (i.e., at least about 70% up to about 100%) the IL-2-induced NK cell proliferation relative to that observed for the reference human IL-2 muteins when these muteins are assayed under similar conditions at protein concentrations of about 1.0 nM down to about 0.05 nM (i.e., about 50 pM).
- IL-2-induced NK proliferation and TNF- ⁇ production are determined using NK-92 cells (i.e., using the NK-92 bioassay disclosed herein), in which NK cell proliferation is determined using a commercially available MTT dye-reduction kit (CellTiter 96® Non-Radioactive Cell Proliferation Assay Kit; available from Promega Corp., Madison, Wisconsin) and a stimulation index is calculated based on a colorimetric readout, and TNF- ⁇ is quantified using a commercially available TNF- ⁇ ELISA kit (BioSource CytoscreenTM Human TNF- ⁇ ELISA kit; Camarillo, California).
- MTT dye-reduction kit CellTiter 96® Non-Radioactive Cell Proliferation Assay Kit
- Human IL-2 muteins within this first functional class include those muteins comprising the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution selected from the group consisting of F42E, V91D, and L72N, where the residue position (i.e., 42, 91, or 72) is relative to the mature human IL-2 sequence (i.e., relative to SEQ ID NO:4).
- the second functional class of human IL-2 muteins includes those muteins that strongly increase NK cell proliferation without deleterious impact on IL-2-induced TNF- ⁇ production by NK cells. Muteins within this functional group meet three selection criteria: (1) level of IL-2-induced NK cell proliferation that is greater than about 200%, of that induced by des-alanyl-1, C125S human IL-2 or C125S human IL-2 at one or more concentrations of human IL-2 mutein selected from the group consisting of 0.005 nM (i.e., 5 pM), 0.02 nM (i.e., 20 pM), 0.05 nM (i.e., 50 pM), 0.1 nM (i.e., 100 pM), or 1.0 nM (i.e., 1000 pM); (2) level of IL-2-induced NK cell proliferation that is greater than about 150% of that induced by des-alanyl-1, C125S human IL-2 or C125S human
- IL-2-induced TNF- ⁇ production by NK cells and IL-2 -induced NK cell proliferation are determined using NK-92 cells (i.e., using the NK-92 bioassay disclosed herein), in which TNF- ⁇ production is measured using ELISA, and NK cell proliferation is measured by an MTT assay as noted herein above.
- Human IL-2 muteins within this second functional class include those muteins comprising the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution selected from the group consisting of L36D and L40D, where the residue position (i.e., 36 or 40) is relative to the mature human IL-2 sequence (i.e., relative to SEQ ID NO:4). See Example 8, and Table 15 herein below.
- the third functional class of human IL-2 muteins includes those muteins that are "bi-functional" in that they induce increased NK cell proliferation and decreased TNF- ⁇ production by NK cells relative to the reference IL-2 muteins.
- Muteins within this third functional class meet the following criteria: (1) induce a level of NK cell proliferation that is at least about 150%> of that observed for des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed for any one mutein concentration selected from the group consisting of 0.005 nM (i.e., 5 pM), 0.02 nM (i.e., 20 pM), 0.05 nM (i.e., 50 pM), 0.1 nM (i.e., 100 pM), or 1.0 nM (i.e., 1000 pM); and (2) induce a level of TNF- ⁇ production by NK cells that is less than about 75%> of that induced by des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at a mutein concentration of about 1.0 nM.
- IL-2-induced TNF- ⁇ production and IL-2-induced NK cell proliferation are determined using NK-92 cells (i.e., the NK-92 bioassay disclosed herein), in which IL-2- induced TNF- ⁇ production is measured using ELISA, and IL-2-induced NK cell proliferation is measured by an MTT assay as noted herein above.
- Human IL-2 muteins within this third functional class include those muteins comprising the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO: 6) with at least one other substitution selected from the group consisting of L19D, F42R, and E61R, where the residue position (i.e., 19, 42, or 61) is relative to the mature human IL-2 sequence (i.e., relative to SEQ ID NO:4). See Example 8, and Table 16 herein below.
- the invention also provides human IL-2 muteins meeting other selection criteria that contribute to an improved therapeutic index relative to that observed for des-alanyl-1 C125S human IL-2 or C125S human IL-2.
- the human IL-2 muteins of the invention induce a level of TNF- ⁇ production by NK cells that is less than about 100%, preferably less than about 95%, or 90%>, more preferably less than about 85% of the level of TNF- ⁇ production by NK cells that is induced by des- alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at a mutein concentration of 1.0 nM, and increase IL-2-induced NK cell proliferation to greater than about 130%) relative to that induced by des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at a mutein concentration of 0.1 nM.
- IL-2- induced TNF- ⁇ production and IL-2-induced NK cell proliferation are determined using NK-92 cells (i.e., using the NK-92 bioassay disclosed herein), in which IL-2-induced TNF- ⁇ production is measured using ELISA, and IL-2 -induced NK cell proliferation is measured by an MTT assay as noted herein above.
- Human IL-2 muteins with these functional criteria comprise the amino acid sequence of des-alanyl-1 , C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution selected from the group consisting of H16D, L19D, L36D, L36P, L40D, L40G, P65L, P65Y, E67A, L72N, L80K, L94Y, E95D, E95G, Y107H, and Y107R, where the residue position (i.e., 16, 19, 36, 40, 65, 67, 72, 80, 94, 95, and 107) is relative to the mature human IL-2 sequence (i.e., relative to SEQ ID NO:4).
- Muteins meeting these functional criteria also exhibit a ratio of IL-2-induced NK cell proliferation at 0.1 nM mutein:IL-2- induced TNF- ⁇ production by NK cells at 1.0 nM mutein that is at least 1.25-fold greater, preferably at least 1.5-fold, 1.75-fold, or 2.0-fold greater, and up to about 2.5-fold to about 2.75-fold greater than that observed for des-alanyl-1, C125S human IL-2 or C125S human IL-2. See also Example 2, and Table 3 herein below, where additional suitable substitutions within the des-alanyl-1, C125S human IL-2 or C125S human IL-2 mutein are listed.
- the human IL-2 muteins of the invention induce a level of TNF- ⁇ production by NK cells that is ⁇ about 100%, of the level of TNF- ⁇ production by NK cells that is induced by des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at a mutein concentration of 1.0 nM, and increase IL-2 -induced NK cell proliferation to greater than about 150% relative to that induced by des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at a mutein concentration of 0.1 nM.
- IL-2-induced TNF- ⁇ production and IL-2-induced NK cell proliferation are determined using NK-92 cells (i.e., using the NK-92 bioassay disclosed herein), in which IL-2-induced TNF- ⁇ production is measured using ELISA, and IL-2 -induced NK cell proliferation is measured by an MTT assay as noted herein above.
- Human IL-2 muteins with these functional criteria comprise the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution selected from the group consisting of L36G, L36H, L40G, and
- P65F where the residue position (i.e., 36, 40, and 65) is relative to the mature human IL- 2 sequence (i.e., relative to SEQ ID NO:4).
- Muteins meeting these functional criteria also exhibit a ratio of IL-2-induced NK cell proliferation at 0.1 nM mutein:IL-2-induced TNF- ⁇ production by NK cells at 1.0 nM mutein that is at least 1.5 -fold greater, preferably at least 2.0-fold greater, and up to about 2.5-fold greater than that observed for des-alanyl-1, C125S human IL-2 or C125S human IL-2. See Example 2, and Table 4 herein below.
- human IL-2 muteins of the invention induce a level of TNF- ⁇ production by NK cells that is greater than and up to about 110%,) the level of TNF- ⁇ production by NK cells that is induced by des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at 1.0 nM concentration, and increase IL-2-induced NK cell proliferation to greater than 150%, relative to that induced by des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at 0.1 nM.
- IL-2-induced TNF- ⁇ production and IL-2 -induced NK cell proliferation are determined using NK-92 cells (i.e., using the NK-92 bioassay disclosed herein), in which IL-2-induced TNF- ⁇ production is measured using ELISA, and IL-2-induced NK cell proliferation is measured by an MTT assay as noted herein above.
- Human IL-2 muteins with these functional criteria comprise the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO: 8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution selected from the group consisting of L36R, K64G, K64L, P65E, P65G, P65T, and P65V, where the residue position (i.e., 36, 64, and 65) is relative to the mature human IL-2 sequence (i.e., relative to SEQ ID NO:4).
- Muteins meeting these functional criteria also exhibit a ratio of IL-2 - induced NK cell proliferation at 0.1 nM mutein.TL-2-induced TNF- ⁇ production by NK cells at 1.0 nM mutein that is at least 1.5-fold greater, preferably at least 1.75-fold greater, and up to about 2.0-fold to about 2.5-fold greater than that observed for des- alanyl-1, C125S human IL-2 or C125S human IL-2. See Example 2, and Table 4 herein below.
- the human IL-2 muteins of the invention induce a level of TNF- ⁇ production by NK cells that is less than about 90%, preferably less than about 80%, of the level of TNF- ⁇ production by NK cells that is induced by des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at 1.0 nM concentration, and induce NK cell proliferation that is at least 95%>, preferably at least 105%,, more preferably at least 120% to about 200%, of that induced by des-alanyl-1 C125S human IL-2 when assayed at 0.1 nM and at 1.0 nM, or which maintain (i.e., at least 70%>, preferably at least 75%>, 80% > , or 85%, more preferably at least 90% up to about 100%) IL-2-induced NK cell proliferation relative to that induced by the C125S human IL-2 mutein at 0.1 nM.
- IL-2-induced TNF- ⁇ production and IL-2-induced NK cell proliferation are determined using NK-92 cells (i.e., using the NK-92 bioassay disclosed herein), in which IL-2-induced TNF- ⁇ production is measured using ELISA, and IL-2-induced NK cell proliferation is measured by an MTT assay as noted herein above.
- Human IL-2 muteins with these functional criteria comprise the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution selected from the group consisting of H16D, L19D, L36D, L36P, F42E, F42R, E61R, P65L, P65Y, E67A, L72N, L80V, R81K, N88D, V91D, L94Y, E95D, E95G, Y107H, and Y107R, where the residue position (i.e., 16, 19, 36, 42, 61, 65, 67, 72, 80, 81, 88, 91, 94, 95, or 107) is relative to the mature human IL-2 sequence (i.e., relative to SEQ ID NO:4).
- Muteins meeting these functional criteria also exhibit a ratio of IL- 2-induced NK cell proliferation at 0.1 nM mutein:IL-2-induced TNF- ⁇ production by NK cells at 1.0 nM mutein that is at least 1.25-fold greater, preferably at least 1.5-fold greater, 1.75-fold greater, 2.0-fold greater, and up to about 2.5-fold to about 2.75-fold greater than that observed for des-alanyl-1, C125S human IL-2 or C125S human IL-2. See Example 3, and Table 5 herein below.
- the IL-2 muteins of the invention induce a level of TNF- ⁇ production by NK cells that is less than about 80%,, preferably less than about 70%, of the level of TNF- ⁇ production by NK cells that is induced by des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at 1.0 nM concentration, and induce NK cell proliferation that is at least 80%, preferably at least 90%, 95%, 100%, or 105%, more preferably at least 110%, to about 150%, of that induced by des-alanyl-1 C125S human IL- 2 when assayed at 1.0 nM.
- IL-2-induced TNF- ⁇ production and IL- 2-induced NK cell proliferation are determined using NK-92 cells (i.e., using the NK-92 bioassay disclosed herein), in which IL-2-induced TNF- ⁇ production is measured using ELISA, and IL-2 -induced NK cell proliferation is measured by an MTT assay as noted herein above.
- Human IL-2 muteins with these functional criteria comprise the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution selected from the group consisting of F78S, F78W, H79F, H79M, H79N, H79P, H79Q, H79S, H79V, L80E, L80F, L80Y, R81E, R81L, R81N, R81P, R81T, N88H, and Q126I, or at least one other substitution selected from the group consisting of E61M, E62T, E62Y, L80G, L80N, L80R, L80W, D84R, N88T, E95M, Y107L, Y107Q, and Y107T, where the residue position (i.e., 61, 62, 78, 79, 80, 81, 84, 88, 95, or 107) is relative to
- the IL-2 muteins of the invention meet the following functional criteria: (1) induce a level of TNF- ⁇ production by NK cells that is less than about 100%, preferably less than about 95%,, 90%>, or 85%,, more preferably less than about 80%, or less than about 75% of the level of TNF- ⁇ production by NK cells that is induced by des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at 1.0 nM concentration; (2) maintain (about 100%) or increase (about 105% up to about 120%) IL-2-induced NK cell proliferation relative to des-alanyl-1 C125S human IL-2 or C125S human IL-2 when assayed at 0.1 nM and 1.0 nM; and (3) improve NK-mediated cytotoxicity activity to greater than about 140%, up to about 160% of that observed for C125S human IL-2 mutein and to greater than about 115%, up to
- IL-2-induced TNF- ⁇ production and IL-2-induced NK cell proliferation are determined using NK-92 cells (i.e., using the NK-92 bioassay disclosed herein), in which IL-2-induced TNF- ⁇ production is measured using ELISA, and IL-2-induced NK cell proliferation is measured by an MTT assay as noted herein above; and NK-mediated cytotoxicity activity against K562 cells is measured, for example, using the NK3.3 cell line in the NK3.3 cytotoxicity bioassay disclosed herein.
- Human IL-2 muteins with these functional criteria comprise the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO: 6) with at least one other substitution selected from the group consisting of P34R, P34T, L36A, L36D, L36P, R38P, F42A, and L80R, where the residue position (i.e., 34, 36, 38, 42, or 80) is relative to the mature human IL-2 sequence (i.e., relative to SEQ ID NO:4) . See Example 4, and Table 8 herein below.
- the IL-2 muteins of the invention are selected for their ability to induce lower levels of pro-inflammatory cytokines predictive of improved toxicity, as well as improved NK cell proliferation activity, and improved LAK-mediated cytotoxicity activity.
- These muteins meet the following functional criteria: (1) induce a level of TNF- ⁇ production that is less than 100%, preferably less than 95%, 90%, 85%, or 80% of that induced by des-alanyl-1, C125S human IL-2 or C125S human IL-2 when assayed at 1.0 nM concentration; (2) maintain (about 100%) or enhance (about 105% up to about 140%,) IL-2-induced NK cell proliferation relative to des-alanyl-1, C125S human IL-2 or C125S human IL-2 when assayed at 1.0 nM or at 0.1 nM; and (3) improve LAK- mediated cytotoxicity activity to greater than about 105%,, preferably greater than about 110%, 115%,, or 120%, up to about 140% of
- IL-2-induced TNF- ⁇ production and IL- 2-induced NK cell proliferation are determined using NK-92 cells (i.e., using the NK-92 bioassay disclosed herein), in which IL-2-induced TNF- ⁇ production is measured using ELISA, and IL-2-induced NK cell proliferation is measured by an MTT assay as noted herein above; and LAK-mediated cytotoxicity activity against Daudi cells is measured using the NK3.3 cell line and the NK3.3 cytotoxicity bioassay disclosed herein.
- Human IL-2 muteins with these functional criteria comprise the amino acid sequence of des- alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution selected from the group consisting of L36P, L36R, F42A, L80R, and V91Q, where the residue position (i.e., 36, 42, 80, or 91) is relative to the mature human IL-2 sequence (i.e., relative to SEQ ID NO:4) . See Example 5, and Table 9 herein below.
- the IL-2 muteins of the invention are selected for their improved toxicity, improved NK cell proliferation activity, and improved ADCC- mediated cytotoxicity activity.
- muteins meet the following functional criteria: (1) induce a level of TNF- ⁇ production that is less than 100%,, preferably less than 95%,, 90%, 85%, or 80% of that induced by des-alanyl-1, C125S human IL-2 or C125S human IL-2 when assayed at 1.0 nM concentration; (2) maintain (at least 90%,) or enhance (about 105% up to about 115%) IL-2-induced NK cell proliferation relative to des-alanyl- 1, C125S human IL-2 or C125S human IL-2 when assayed at 1.0 nM or at 0.1 nM; and (3) improve ADCC-mediated cytotoxicity activity to greater than about 105%, preferably greater than about 110% or 115%,, up to about 120%, of that induced by des-alanyl-1, C125S human IL-2 or C125S human IL-2.
- IL-2-induced TNF- ⁇ production and IL-2-induced NK cell proliferation are determined using NK-92 cells (i.e., using the NK-92 bioassay disclosed herein), in which IL-2-induced TNF- ⁇ production is measured using ELISA, and IL-2-induced NK cell proliferation is measured by an MTT assay as noted herein above; and ADCC-mediated cytotoxicity activity against Daudi cells in the presence of antibody, such as Rituxan® (rituximab; IDEC-C2B8; IDEC Pharmaceuticals Corp., San Diego, California) is measured using the NK3.3 cell line and the NK3.3 cytotoxicity bioassay disclosed herein.
- Rituxan® rituximab
- IDEC-C2B8 IDEC Pharmaceuticals Corp., San Diego, California
- Human IL-2 muteins with these functional criteria comprise the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution selected from the group consisting of D20E or E67A, where the residue position (i.e., 20 or 67) is relative to the mature human IL-2 sequence (i.e., relative to SEQ ID NO:4). See Example 6, and Table 10 herein below.
- the IL-2 muteins maintain or enhance NK cell survival relative to that observed for the reference IL-2 muteins, as measured by a pAKT ELISA assay using NK 3.3 cells.
- Human IL-2 muteins with these functional attributes comprise the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO:8) or C125S human IL-2 (SEQ ID NO: 6) with at least one other substitution selected from the group consisting of L40D, L40G, L80K, R81K, L94Y, and E95D, where the residue position (i.e., 40, 80, 81, 94, or 95) is relative to the mature humanIL-2 sequence (i.e., relative to SEQ ID NO:4). See Example 7, and Table 11 herein below, which shows other suitable muteins that meet these functional criteria.
- the present invention also provides biologically active variants of the novel human IL-2 muteins disclosed herein that also have these improved properties relative to the reference IL-2 molecule, i.e., the biologically active variants induce low or reduced pro-inflammatory cytokine production by NK cells, as well as maintain or increase NK cell proliferation, when compared to the reference IL-2 molecule, i.e., des-alanyl-1 C125S or C125S human IL-2, using the standard bioassays disclosed elsewhere herein.
- any given novel human IL-2 mutein identified herein may have a different absolute level of a particular biological activity relative to that observed for the novel human IL-2 mutein of the invention, so long as it has the desired characteristics relative to the reference IL-2 molecules, i.e., reduced toxicity, that is reduced pro-inflammatory cytokine production, and/or increased NK cell proliferation when compared to the reference human IL-2 mutein.
- variant is intended substantially similar sequences.
- Variants of the novel human IL-2 muteins described herein may be derived from naturally occurring (e.g., allelic variants that occur at the IL-2 locus) or recombinantly produced (for example muteins) nucleic acid or amino acid sequences.
- Polypeptide variants can be fragments of the novel human IL-2 muteins disclosed herein, or they can differ from the novel human IL-2 muteins by having one or more additional amino acid substitutions or deletions, or amino acid insertions, so long as the variant polypeptide retains the particular amino acid substitutions of interest that are present within the novel human IL-2 muteins disclosed herein.
- suitable polypeptide variants include those with the C125S substitution corresponding to position 125 of the mature human IL-2 sequence (i.e., SEQ ID NO:4), the second amino acid substitution identified herein as contributing to the improved therapeutic index of the novel human IL-2 muteins of the present invention (i.e., a substitution shown in Table 1 above, preferably a substitution shown in Table 12 below), and which have one or more additional amino acid substitutions or deletions, or amino acid insertions.
- novel human IL-2 mutein comprises the amino acid sequence of des-alanyl-1, C125S human IL-2 (SEQ ID NO: 8) or C125S human IL-2 (SEQ ID NO:6) with at least one other substitution selected from the group shown in Table 1
- suitable biologically active variants of these novel human IL-2 muteins will also comprise the C125S substitution as well as the other substitution represented by those mutations shown in Table 1, but can differ from the respective novel human IL-2 mutein in having one or more additional substitutions, insertions, or deletions, so long as the variant polypeptide has the desired characteristics relative to the reference IL-2 molecules (i.e., C125S human IL-2 and des-alanyl-1, C125S human IL-2), and thus has reduced toxicity, that is reduced pro-inflammatory cytokine production, and/or increased NK cell proliferation when compared to the reference human IL-2 mutein.
- Such variants will have amino acid sequences that are at least 70%, generally at least 75%>, 80%o, 85%,, 90% identical, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence for the respective novel human IL-2 mutein, for example, the human IL-2 mutein set forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142,
- the biologically active variants will have amino acid sequences that are at least 70%, generally at least 75%, 80%, 85%, 90% identical, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence set forth in residues 2-133 of SEQ ID NO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152,
- biologically active variants of the human IL-2 muteins of the invention have the C125S substitution replaced with another neutral amino acid such as alanine, which does not affect the desired functional characteristics of the human IL-2 mutein.
- such variants have an amino acid sequence that comprises an alanine residue substituted for the serine residue at position 125 of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98,
- the biologically active variants of the human IL-2 muteins of the invention comprise residues 2-133 of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158
- the biologically active variants of the human IL-2 muteins of the invention comprise residues 2-133 of SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188,
- nucleic acid “variant” is intended a polynucleotide that encodes a novel human IL-2 mutein of the invention but whose nucleotide sequence differs from the novel mutein sequence disclosed herein due to the degeneracy of the genetic code. Codons for the naturally occurring amino acids are well known in the art, including those codons that are most frequently used in particular host organisms used to express recombinant proteins.
- the nucleotide sequences encoding the IL-2 muteins disclosed herein include those set forth in the accompanying Sequence Listing, as well as nucleotide sequences that differ from the disclosed sequences because of degeneracy in the genetic code.
- the nucleotide sequence encoding the substituted alanine residue can be selected from the four universal triplet codons for alanine, i.e., GCA, GCC, GCG, and GCT.
- the IL-2 mutein of the invention comprises an aspartic acid (i.e., D) substitution, such as in the C125S or des-alanyl C125S mutein comprising the T7D, K9D, H16D, L19D, K35D, L36D, R38D, L40D, K64D, P65D, N88D, V91D, or E95D substitution
- the nucleotide sequence encoding the substituted aspartic acid residue can be selected from the two universal triplet codons for aspartic acid, i.e., GAC and GAT.
- the IL-2 mutein of the invention comprises an arginine (i.e., R) substitution, such as in the C125S or des-alanyl C125S mutein comprising the T7R, K9R, Ql 1R, P34R, L36R, F42R, E61R, K64R, P65R, L80R, D84R, or Y107R substitution
- the nucleotide sequence encoding the substituted arginine residue can be selected from the four universal triplet codons for arginine, i.e., CGT, CGC, CGA, and CGG.
- the nucleotide sequence encoding the substituted leucine residue can be selected from the six universal triplet codons for leucine, i.e., TTA, TTG, CTT, CTC, CTA, and CTG.
- the nucleotide sequence encoding the substituted serine residue can be selected from the two universal triplet codons for serine, i.e., AGT and AGC.
- the nucleotide sequence encoding the substituted valine residue can be selected from the four universal triplet codons for valine, i.e., GTT, GTC, GTA, and GTG.
- the IL-2 mutein of the invention comprises a lysine (i.e., K) substitution, such as in the C125S or des-alanyl C125S mutein comprising the T10K, L36K, F44K, E61K, P65K, L80K, R81K, E106K, or Y107K substitution
- the nucleotide sequence encoding the substituted lysine residue can be selected from the two universal triplet codons for lysine, i.e., AAA and AAG.
- the nucleotide sequence encoding the substituted asparagine residue can be selected from the two universal triplet codons for asparagine, i.e., GAT and GAC.
- the IL-2 mutein of the invention comprises a threonine (i.e., T) substitution, such as in the C125S or des-alanyl C125S mutein comprising the Ql IT, P34T, K35T, F42T, E62T, P65T, L72T, L80T, R81T, S87T, N88T, L94T, or Y107T substitution
- the nucleotide sequence encoding the substituted threonine residue can be selected from the four universal triplet codons for threonine, i.e., ACT, ACC, and ACA, ACG.
- the IL-2 mutein of the invention comprises a glutamic acid (i.e., E) substitution, such as in the C125S or des-alanyl C125S mutein comprising the H16E, L19E, D20E, N33E, P34E, L36E, T41E, F42E, K64E, P65E, L80E, R81E, or V91E substitution
- the nucleotide sequence encoding the substituted glutamic acid residue can be selected from the two universal triplet codons for glutamic acid, i.e., GAA and GAG.
- the nucleotide sequence encoding the substituted isoleucine residue can be selected from the three universal triplet codons for isoleucine, i.e., ATT, ATC, and ATA.
- the nucleotide sequence encoding the substituted proline residue can be selected from the four universal triplet codons for proline, i.e., CCT, CCC, CCA, and CCG.
- the nucleotide sequence encoding the substituted glutamine residue can be selected from the two universal triplet codons for glutamine, i.e., CAA and CAG.
- the nucleotide sequence encoding the substituted phenylalanine residue can be selected from the two universal triplet codons for phenylalanine, i.e., TTT and TTC.
- the IL-2 mutein of the invention comprises a glycine (i.e., G) substitution, such as in the C125S or des-alanyl C125S mutein comprising the L36G, R38G, L40G, T41G, K64G, P65G, L72G, L80G, V91G, E95G, M104G, or E116G substitution
- the nucleotide sequence encoding the substituted glycine residue can be selected from the four universal triplet codons for glycine, i.e., GGT, GGC, GGA, and GGG.
- the nucleotide sequence encoding the substituted histidine residue can be selected from the two universal triplet codons for histidine, i.e., CAT and CAC.
- the nucleotide sequence encoding the substituted tyrosine residue can be selected from the two universal triplet codons for tyrosine, i.e., TAT and TAG.
- the nucleotide sequence encoding the substituted cysteine residue can be selected from the two universal triplet codons for cysteine, i.e., TGT and TGC.
- TGT and TGC the universal triplet codons for cysteine
- Naturally occurring allelic variants of native human IL-2 can be identified with the use of well-known molecular biology techniques, such as polymerase chain reaction (PCR) and hybridization techniques, and can serve as guidance to the additional mutations that can be introduced into the human IL-2 muteins disclosed herein without impacting the desired therapeutic index of these novel human IL-2 muteins.
- Variant nucleotide sequences also include muteins derived from synthetically derived nucleotide sequences that have been generated, for example, by site-directed mutagenesis but which still encode the novel IL-2 muteins disclosed herein, as discussed below.
- nucleotide sequence variants of the invention will have at least 70%, generally at least 75%, 80%, 85%, 90% sequence identity, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 91%, 98%, or 99% sequence identity to their respective novel human IL-2 mutein nucleotide sequences, for example, with respect to a novel human IL-2 mutein coding sequence set forth in SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127,
- nucleotide sequence variants of the invention will have at least 70%>, generally at least 75%, 80%, 85%, 90% sequence identity, preferably at least 91%,, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to nucleotides 4-399 of the coding sequence set forth in SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141,
- the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding an IL-2 mutein of the invention.
- the phrase “allelic variant” refers to a nucleotide sequence that occurs at an IL-2 locus or to a polypeptide encoded by that nucleotide sequence. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the IL-2 gene.
- nucleotide variations and resulting amino acid polymorphisms or variations in a IL-2 sequence that are the result of natural allelic variation and that do not alter the functional activity of the novel human IL-2 muteins of the invention are intended to be sequences which can be mutated according to the present invention, and all of the resulting sequences are intended to fall within the scope of the invention.
- amino acid sequence variants of the novel human IL-2 muteins disclosed herein can be prepared by making mutations in the cloned DNA sequence encoding the novel IL-2 mutein, so long as the mutation(s) does not alter the additional substitution identified in Table 1. Methods for mutagenesis and nucleotide sequence alterations are well known in the art.
- amino acids with basic side chains e.g., lysine, arginine, histidine
- acidic side chains e.g., aspartic acid, glutamic acid
- uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
- nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
- beta-branched side chains e.g., threonine, valine, isoleucine
- aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
- variants of a novel human IL-2 mutein of the invention modifications to the nucleotide sequences encoding the variants will be made such that variant polypeptides may continue to possess the desired activity.
- any mutations made in the DNA encoding a variant polypeptide must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure.
- a variant of a polypeptide may differ by as few as 1 to 15 amino acid residues, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue.
- a variant of a nucleotide sequence may differ by as few as 1 to 30 nucleotides, such as 6 to 25, as few as 5, as few as 4, 3, 2, or even 1 nucleotide.
- Biologically active variants of the human IL-2 muteins of the invention include fragments of these muteins.
- fragment is intended a portion of the coding nucleotide sequence or a portion of the amino acid sequence.
- fragments of a human IL-2 mutein nucleotide sequence may encode mutein fragments that retain the desired biological activity of the novel human IL-2 mutein.
- a fragment of a novel human IL-2 mutein disclosed herein may be 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130 amino acids or up to the full length of the novel human IL-2 polypeptide.
- Fragments of a coding nucleotide sequence may range from at least 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270, 285, 300, 315, 330, 345, 360, 375, 390, nucleotides, and up to the entire nucleotide sequence encoding the novel human IL-2 mutein.
- the human IL-2 muteins disclosed herein and biologically active variants thereof may be modified further so long as they have the desired characteristics relative to the reference IL-2 molecules, i.e., reduced toxicity and/or increased NK cell proliferation relative to the C125S human IL-2 or des-alanyl-1, C125S human IL-2 mutein. Further modifications include, but are not limited to, phosphorylation, substitution of non-natural amino acid analogues, and the like. Modifications to IL-2 muteins that may lead to prolonged in vivo exposure, and hence increase efficacy of the IL-2 mutein pharmaceutical formulations, include glycosylation or PEGylation of the protein molecule.
- Glycosylation of proteins not natively glycosylated is usually performed by insertion of N-linked glycosylation sites into the molecule. This approach can be used to prolong half-life of proteins such as IL-2 muteins. hi addition, this approach can be used to shield immunogenic epitopes, increase protein solubility, reduce aggregation, and increase expression and purification yields.
- the deletions, insertions, and substitutions of the human LL-2 mutein sequences are not expected to produce radical changes in the characteristics of the particular human IL-2 mutein.
- the effect will be evaluated by routine screening assays. That is, the IL-2-induced NK or T cell proliferation activity can be evaluated by standard cell proliferation assays known to those skilled in the art, including the assays described herein. IL-2-induced pro- inflammatory cytokine production may be measured using cytokine-specific ELIS As, for example, the TNF- ⁇ specific ELISA noted elsewhere herein. NK cell survival signaling may be measured by a pAKT ELISA (see, for example, the assay described herein below).
- NK cell-mediated cytolytic activity may be measured by assays known in the art (for example, measurement of NK-mediated, LAK-mediated, or ADCC-mediated cytolytic activity as noted elsewhere herein).
- the human IL-2 muteins disclosed herein, and biologically active variants thereof can be constructed as IL-2 fusions or conjugates comprising the IL-2 mutein (or biologically active variant thereof as defined herein) fused to a second protein or covalently conjugated to polyproline or a water-soluble polymer to reduce dosing frequencies or to further improve IL-2 tolerability.
- the human IL-2 mutein (or biologically active variant thereof as defined herein) can be fused to human albumin or an albumin fragment using methods known in the art (see, for example, WO 01/79258).
- the human IL-2 mutein (or biologically active variant thereof as defined herein) can be covalently conjugated to polyproline or polyethylene glycol homopolymers and polyoxyethylated polyols, wherein the homopolymer is unsubstituted or substituted at one end with an alkyl group and the poplyol is unsubstituted, using methods known in the art (see, for example, U.S. Patent Nos. 4,766,106, 5,206,344, and 4,894,226).
- sequence identity is intended the same nucleotides or amino acid residues are found within the variant sequence and a reference sequence when a specified, contiguous segment of the nucleotide sequence or amino acid sequence of the variant is aligned and compared to the nucleotide sequence or amino acid sequence of the reference sequence.
- Methods for sequence alignment and for dete ⁇ nining identity between sequences are well known in the art. See, for example, Ausubel et al, eds. (1995) Current Protocols in Molecular Biology, Chapter 19 (Greene Publishing and Wiley- Interscience, New York); and the ALIGN program (Dayhoff (1978) m Atlas of Polypeptide Sequence and Structure J:Suppl. 3 (National Biomedical Research).
- the contiguous segment of the variant nucleotide sequence may have additional nucleotides or deleted nucleotides with respect to the reference nucleotide sequence.
- the contiguous segment of the variant amino acid sequence may have additional amino acid residues or deleted amino acid residues with respect to the reference amino acid sequence.
- the contiguous segment used for comparison to the reference nucleotide sequence or reference amino acid sequence will comprise at least 20 contiguous nucleotides, or amino acid residues, and maybe 30, 40, 50, 100, or more nucleotides or amino acid residues.
- corrections for increased sequence identity associated with inclusion of gaps in the variant's nucleotide sequence or amino acid sequence can be made by assigning gap penalties.
- Methods of sequence alignment are well known in the art. The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For purposes of the present invention, percent sequence identity of an amino acid sequence is determined using the Smith- Waterman homology search algorithm using an affine 6 gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix 62. The Smith- Waterman homology search algorithm is taught in Smith and Waterman (1981) Adv. Appl Math 2:482-489.
- percent identity of a nucleotide sequence is determined using the Smith- Waterman homology search algorithm using a gap open penalty of 25 and a gap extension penalty of 5. Such a determination of sequence identity can be performed using, for example, the DeCypher Hardware Accelerator from TimeLogic. It is further recognized that when considering percentage of amino acid identity, some amino acid positions may differ as a result of conservative amino acid substitutions, which do not affect properties of polynucleotide function. In these instances, percent sequence identity may be adjusted upwards to account for the similarity in conservatively substituted amino acids. Such adjustments are well known in the art. See, for example, Meyers et al. (1988) Computer Applic. Biol Sci. 4:11-11.
- the human IL-2 muteins of the invention will be expressed from vectors, preferably expression vectors.
- the vectors are useful for autonomous replication in a host cell or may be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome (e.g., nonepisomal mammalian vectors).
- Expression vectors are capable of directing the expression of coding sequences to which they are operably linked.
- expression vectors of utility in recombinant DNA teclmiques are often in the form of plasmids (vectors).
- the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retro viruses, adeno viruses, and adeno- associated viruses).
- the expression constructs or vectors of the invention comprise a nucleic acid molecule encoding a human IL-2 mutein of the present invention in a form suitable for expression of the nucleic acid molecule in a host cell.
- the coding sequence of interest can be prepared by recombinant DNA techniques as described, for example, by
- nucleotide sequences also lack a translation termination codon following the nucleotide at position 399 of odd SEQ ID NOS:9-343.
- sequences, or sequences comprising nucleotides 4-399 of odd SEQ ID NOS:9-343 are to be used to express the human IL-2 muteins of the invention, it is recognized that the expression construct comprising these human IL-2 mutein coding sequences will further comprise a translation initiation codon, for example, an ATG codon, upstream and in proper reading frame with the human IL-2 mutein coding sequence.
- the translation initiation codon can be provided at an upstream location from the initial codon of the human IL-2 mutein coding sequence by utilizing a translation initiation codon, for example ATG, that is already in a sequence that comprises the human IL-2 mutein coding sequence, or can otherwise be provided from an extraneous source such as the plasmid to be used for expression, providing that the translation initiation codon first appearing before the initial codon in the human IL-2 mutein coding sequence is in proper reading frame with the initial codon in the human IL-2 mutein coding sequence.
- a translation initiation codon for example ATG
- the human IL-2 mutein coding sequence disclosed herein will be followed by one or more translation termination codons, for example, TGA, to allow for production of a human IL-2 mutein that ends with the last amino acid of the sequence set forth in even SEQ ID NOS: 10-344.
- the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, operably linked to the nucleic acid sequence to be expressed.
- operably linked is intended to mean that the nucleotide sequence of interest (i.e., a sequence encoding a human IL-2 mutein of the present invention) is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- regulatory sequences include promoters, enhancers, and other expression control elements (e.g., polyadenylation signals). See, for example, Goeddel (1990) in Gene Expression Technology: Methods in Enzymology 185 (Academic Press, San Diego, California).
- Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like.
- the expression constructs of the invention can be introduced into host cells to thereby produce the human IL-2 muteins disclosed herein or to produce biologically active variants thereof.
- the expression constructs or vectors of the invention can be designed for expression of the human IL-2 mutein or variant thereof in prokaryotic or eukaryotic host cells.
- the recombinant human IL-2 muteins or biologically active variants thereof can also be made in eukaryotes, such as yeast or human cells.
- eukaryotic host cells include insect cells (examples of Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) Mol. Cell Biol.
- yeast cells examples include pYepSecl (Baldari et al. (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz (1982) Cell 30:933-943), pJRY88 (Schultz et al.
- mammalian expression vectors include ⁇ CDM8 (Seed (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187:195)).
- Suitable mammalian cells include Chinese hamster ovary cells (CHO) or COS cells.
- the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus, and Simian Virus 40.
- codons can be optimized, for example, the codons where residue substitutions have been made, for example, the C125S substitution, the C125A substitution, and/or the additional substitution indicated in Table 1.
- other codons within the human IL-2 mutein coding sequence can be optimized to enhance expression in the host cell, such that 1%, 5%, 10%, 25%, 50%, 75%, or up to 100% of the codons within the coding sequence have been optimized for expression in a particular host cell. See, for example, the human IL-2 mutein sequences disclosed in SEQ ID NOS:345 and 346, where the codons for the E61R and Y107R substitutions, respectively, have been optimized for expression in E. coli.
- host cell and "recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subj ect cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell but are still included within the scope of the term as used herein.
- Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
- transformation and transfection are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, particle gun, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York) and other standard molecular biology laboratory manuals.
- Prokaryotic and eukaryotic cells used to produce the IL-2 muteins of this invention and biologically active variants thereof are cultured in suitable media, as described generally in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).
- compositions After the human IL-2 muteins or variants thereof are produced and purified, they may be incorporated into a pharmaceutical composition for application in human and veterinary therapeutics, such as cancer therapy or prevention, immunotherapy, and the treatment or prevention of infectious diseases.
- the human IL-2 muteins or biologically active variants thereof can be formulated as pharmaceutical formulations for a variety of therapeutic uses.
- the human IL-2 muteins or biologically active variants thereof are parenterally administered to the subject by methods known in the art.
- Subjects include mammals, e.g., primates, humans, dogs, cattle, horses, etc. These pharmaceutical compositions may contain other compounds that increase the effectiveness or promote the desirable qualities of the human IL-2 muteins of the invention.
- the pharmaceutical compositions must be safe for administration via the route that is chosen, they must be sterile, retain bioactivity, and they must stably solubilize the human IL-2 mutein or biologically active variant thereof.
- the IL-2 mutein pharmaceutical compositions of the invention can be stored in liquid form either ambient, refrigerated, or frozen, or prepared in the dried form, such as a lyophilized powder, which can be reconstituted into the liquid solution, suspension, or emulsion before administration by any of various methods including oral or parenteral routes of administration.
- Such pharmaceutical compositions typically comprise at least one human IL-2 mutein, biologically active variant thereof, or a combination thereof, and a pharmaceutically acceptable carrier.
- compositions for formulating the human IL-2 muteins of the invention for pharmaceutical administration are known to those of skill in the art. See, for example, Gennaro (ed.) (1995) Remington: The Science and Practice of Pharmacy (19 th ed., Mack Publishing Company, Easton, PA).
- pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical adniinistration. The use of such media and agents for pharmaceutically active substances is well known in the art.
- an IL-2 mutein pharmaceutical composition comprising a human IL-2 mutein of the invention or variant thereof is formulated to be compatible with its intended route of administration. The route of administration will vary depending on the desired outcome.
- the IL-2 mutein pharmaceutical composition can be administered by bolus dose, continuous infusion, or constant infusion (infusion for a short period of time, i.e. 1-6 hours).
- the IL-2 mutein pharmaceutical composition can be administered orally, intranasally, parenterally, including intravenously, subcutaneously, intraperitoneally, intramuscularly, etc., by intradermal, transdermal (topical), transmucosal, and rectal administration, or by pulmonary inhalation.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as EDTA; surfactants such as polysorbate 80; SDS; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers for intravenous administration include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
- Sterile inj ectable solutions can be prepared by incorporating the active compound
- dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above, h the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze- drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets.
- the agent can be contained in enteric forms to survive the stomach or further coated or mixed to be released in a particular region of the Gl tract by known methods.
- the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules.
- Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound i the fluid carrier is applied orally and swished and expectorated or swallowed.
- Pharmaceutically compatible bhiding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or co starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppe ⁇ nint, methyl salicylate, or orange flavoring.
- Systemic administration can also be by transmucosal or transdermal means.
- penevers appropriate to the barrier to be permeated are used in the formulation.
- penevers are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
- Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811. It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
- Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
- the human IL-2 muteins of the present invention, or biologically active variants thereof, can be formulated using any known formulation process known in the art for human IL-2. Suitable formulations that are useful in the present method are shown in various patents and publications. For example, U.S. Patent No.
- 4,604,377 shows a preferred IL-2 formulation that has a therapeutic amount of IL-2, which is substantially free from non-IL-2 protein and endotoxin, a physiologically acceptable water-soluble carrier, and a sufficient amount of a surface active agent to solubilize the IL-2, such as sodium dodecyl sulfate. Other ingredients can be included, such as sugars.
- U.S. Patent No. 4,766,106 shows formulations including polyethylene glycol (PEG) modified IL-2.
- IL-2 formulated with various non-ionic surfactants selected from the group consisting of polyoxyethylene sorbitan fatty acid esters (Tween-80), polyethylene glycol monostearate, and octylphenoxy polyethoxy ethanol compounds (Triton X405).
- Tween-80 polyoxyethylene sorbitan fatty acid esters
- Triton X405 polyethylene glycol monostearate
- Triton X405 octylphenoxy polyethoxy ethanol compounds
- 6,525,102 discloses IL-2 formulations comprising an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide.
- Copending U.S. Patent Application No. 10/408,648 discloses IL-2 formulations suitable for pulmonary delivery.
- compositions comprising the human IL-2 muteins of the present invention or biologically active variants thereof obtained from these human IL-2 muteins are useful in the stimulation of the immune system, and in the treatment of cancers, such as those currently treated using native human IL-2 or Proleukin® IL-2.
- the human IL-2 muteins of the present invention and suitable biologically active variants thereof have the advantage of reducing pro-inflammatory cytokine production predictive of having lower toxicity, while maintaining or enhancing desirable functional activities such as NK cell proliferation, survival, NK-mediated cytotoxicity (NK, LAK, and ADCC), and T cell proliferation.
- the human IL-2 muteins of the present invention can be administered at similar or higher doses than can native IL- 2 or Proleukin® IL-2 while minhnizing toxicity effects.
- the present invention provides a method for reducing interleukin-2 (IL-2)-induced toxicity symptoms in a subject undergoing IL-2 administration as a treatment protocol, where the method comprising administering the IL-2 as an IL-2 mutein disclosed herein.
- IL-2 interleukin-2
- human IL-2 muteins of the present invention and suitable biologically active variants thereof have the additional advantage of greater therapeutic efficacy, so that lower doses of these human IL-2 muteins can provide greater therapeutic efficacy than comparable doses of native IL-2 or Proleukin® IL-2.
- a pharmaceutically effective amount of an IL-2 mutein pharmaceutical composition of the invention is administered to a subject.
- pharmaceutically effective amount is intended an amount that is useful in the treatment, prevention or diagnosis of a disease or condition.
- subject is intended mammals, e.g., primates, humans, dogs, cats, cattle, horses, pigs, sheep, and the like.
- the subject undergoing treatment with the pharmaceutical formulations of the invention is human.
- administration When administration is for the purpose of treatment, administration may be for either a prophylactic or therapeutic purpose.
- the substance When provided prophylactically, the substance is provided in advance of any symptom.
- the prophylactic administration of the substance serves to prevent or attenuate any subsequent symptom.
- the substance When provided therapeutically, the substance is provided at (or shortly after) the onset of a symptom.
- the therapeutic administration of the substance serves to attenuate any actual symptom.
- fo ⁇ nulations comprising an effective amount of a pharmaceutical composition of the invention comprising a human IL-2 mutein of the invention or biologically active variant thereof can be used for the purpose of treatment, prevention, and diagnosis of a number of clinical indications responsive to therapy with IL-2.
- the human IL-2 muteins of the present invention and biologically active variants thereof can be formulated and used in the same therapies as native-sequence IL-2 or Proleukin® IL-2. Accordingly, formulations of the invention comprising a human IL-2 mutein of the invention or biologically active variant thereof are useful for the diagnosis, prevention, and treatment (local or systemic) of bacterial, viral, parasitic, protozoan and fungal infections; for augmenting cell-mediated cytotoxicity; for stimulating lymphokine activated killer (LAK) cell activity; for mediating recovery of immune function of lymphocytes; for augmenting alloantigen responsiveness; for facilitating immune reconstitution in cancer patients following radiotherapy, or following or in conjunction with chemotherapy alone or in combination with other anti-cancer agents, or following or in conjunction with bone marrow or autologuos stem cell transplantation; for facilitating recovery of immune function in acquired innnune deficient states; for reconstitution of normal immuno function in aged humans and animals; in the development of diagnostic assays such as those employ
- Formulations of the invention comprising a human IL-2 mutein of the invention or biologically active variant thereof may be used as the single therapeutically active agent or may be used in combination with other immunologically relevant cells or other therapeutic agents.
- exemplary therapeutic reagents that may be used in combination with IL-2 or variant thereof are the various interferons, especially gamma interferon, B-cell growth factor, IL-1, and antibodies, including, but not limited to, anti-HER2 antibodies such as Herceptin ® (Genentech, Inc., San Francisco, California) or anti-CD20 antibodies such as Rituxan® (Rituximab; IDEC-C2B8; IDEC Pharmaceuticals Corp., San Diego, California).
- anti-HER2 antibodies such as Herceptin ® (Genentech, Inc., San Francisco, California) or anti-CD20 antibodies such as Rituxan® (Rituximab; IDEC-C2B8; IDEC Pharmaceuticals Corp., San Diego, California).
- the amount of human IL-2 mutein or biologically active variant thereof administered may range between about 0.1 to about 15 mlU/m 2 .
- Therapeutically effective doses and particular treatment protocols for IL-2 immunotherapy in combination with anti-cancer monoclonal antibodies are known in the art. See, for example, the doses and treatment protocols disclosed in copending U.S. Patent Application Publication Nos. 2003-0185796, entitled Methods of Therapy for Non- Hodgkin 's Lymphoma," and 20030235556, entitled “Combination IL-2/Anti-HER2 Antibody Therapy for Cancers Characterized by Overexpression of the HER2 Receptor Protein, and copending U.S. Patent Application No. 60/491,371, entitled “Methods of Therapy for Chronic Lymphocytic Leukemia," Attorney Docket No. 59516-278, filed July 31, 2003.
- the human IL-2 mutein or biologically active variant thereof may be administered as a high- dose intravenous bolus at 300,000 to 800,000 IU/kg/8 hours.
- the human IL-2 mutein or biologically active variant thereof may be administered as a high- dose intravenous bolus at 300,000 to 800,000 IU/kg/8 hours.
- U.S. patent applications for recommended doses for IL-2 immunotherapy for B-cell lymphomas, HER2 + cancers such as breast cancer, and CLL.
- Use of IL-2 immunotherapy for the treatment of HIV infection is also known in the art. See, for example, U.S. Patent No. 6,579,521, for recommended doses and protocols for this clinical indication.
- the invention provides a method for the treatment of cancer in a subject or for modulating the immune response in a subject, comprising administering a therapeutically effective amount of a human IL-2 mutein of the invention or biologically active variant thereof.
- the "therapeutically effective amount” refers to a dosage level sufficient to induce a desired biological result without inducing unacceptable toxicity effects. Amounts for administration may vary based upon the concentration of human IL-2 mutein or variant thereof within the pharmaceutical composition, the desired activity, the disease state of the mammal being treated, the dosage form, method of administration, frequency of administration, and patient factors such as age, sex, and severity of disease.
- an IL-2 mutein pharmaceutical composition of the invention will comprise the human IL-2 mutein or variant thereof in a concentration range which is greater than that used for Proleukin® IL-2.
- the subject should be closely monitored to determine if toxic side effects appear.
- Such clinical experimental analyses are well- known to those of skill in the art, and would, for example, have been used to established the current doses of Proleukin® IL-2 for use in immunomodulation and cancer therapy.
- Bioassays for Monitoring Functional Activity of Human IL-2 Muteins The present invention also provides novel bioassays for monitoring IL-2 induced NK cell proliferation and TNF- ⁇ production, IL-2-induced NK cell-mediated cytotoxicity, IL-2 -induced T cell proliferation, and LL-2-induced NK cell survival.
- NK-92 bioassay which monitors IL-2 induction of TNF- ⁇ production and IL-2-induced NK cell proliferation.
- This bioassay utilizes the human NK-92 cell line (ATCC CRL-2407, CMCC ID #11925).
- the NK-92 cell line originally described by Gong et al. (1994) Leukemia 8(4):652-658, displays phenotypic and functional characteristics of activated NK cells. Proliferation of NK-92 is IL-2 dependent; cells will die if cultured in the absence of IL-2 for 72 hours. The cell line also produces detectable levels of TNF- ⁇ within 48-72 hours following exposure to IL-2.
- candidate IL-2 muteins can be screened for relative ability to induce TNF- ⁇ production and induce NK cell proliferation using this NK-92 bioassay.
- NK-92 cells are cultured in complete medium (NK-92 medium) consisting of Alpha-MEM, 12% heat-inactivated fetal bovine serum (FBS), 8%, heat-inactivated horse serum, 0.02 mM folic acid, 0.2 mM inositol, 2 mM L-glutamine, and 0.1 mM ⁇ -mercaptoethanol. Cultures are seeded at a minimum density of 1-3 x 10 5 cells/ml and supplemented with 1000 IU/ml of the reference recombinant human IL-2 mutein (for example, the reference IL-2 mutein designated des-alanyl-1, C125S human IL-2 or the reference C125S human IL-2 mutein).
- IL-2 mutein for example, the reference IL-2 mutein designated des-alanyl-1, C125S human IL-2 or the reference C125S human IL-2 mutein.
- NK-92 In preparation for the assay, cells are placed in fresh NK-92 medium a minimum of 48 h prior to assay use. One day prior to assay, NK-92 are washed three times and placed in NK-92 medium without any supplemental IL-2 for 24 h. Cells are centrifuged, suspended in NK-92 medium (no IL-2) and plated into 96-well flat bottom plates at a density of 4 x 10 4 cells/well in 200 ⁇ l with varying concentrations of the reference IL-2 mutein, for example, des-alanyl-1 C125S or C125S human IL-2, or varying concentrations of a candidate IL-2 mutein that is being screened for the functional profile of interest diluted in NK-92 medium.
- the reference IL-2 mutein for example, des-alanyl-1 C125S or C125S human IL-2, or varying concentrations of a candidate IL-2 mutein that is being screened for the functional profile of interest diluted in
- TNF- ⁇ ELISA kit for example, BioSource CytoscreenTM Human TNF- ⁇ ELISA kit; Camarillo, California.
- proliferation is determined using a commercially available MTT dye-reduction kit (CellTiter 96® Non-Radioactive Cell Proliferation Assay Kit (Promega Corp., Madison, Wisconsin), and a stimulation index is then calculated based on a colorimetric readout.
- the second IL-2 bioassay disclosed herein provides a method for screening candidate IL-2 muteins for their ability to induce natural killer (NK) cell-mediated cytotoxicity.
- This bioassay designated the "NK3.3 cytotoxicity bioassay," utilizes the human NK3.3 cell line.
- the NK3.3 cell line displays phenotypic and functional characteristics of peripheral blood NK cells (Kornbluth (1982) J Immunol 129(6):2831- 2837), and can mediate antibody-dependent cellular cytotoxicity (ADCC) via the Fc receptor (CD 16, Fc ⁇ RIIIA).
- Table 2 in the Experimental section below summarizes the biological activities of NK3.3 cells examined with this LL-2 bioassay.
- candidate IL-2 muteins can be screened for their cytotoxicity activity using this NK3.3 cytotoxocity bioassay.
- NK3.3 cells are expanded and maintained in RPMI-1640 medium supplemented with 15%> heat-inactivated fetal bovine serum, 25 mM HEPES, 2 mM L- glutamine, and 20% Human T-StimTM w/PHA as a source of IL-2.
- NK3.3 cells are cultured in the absence of IL-2 ("starved) for 24 h.
- the assay consists of 5 x 10 4 "starved" NK3.3 cells plated in U-bottom 96-well plates, exposed to varying concentrations of a reference IL-2 mutein, for example, des-alanyl-1, C125S or C125S human IL-2 mutein, or varying concentrations of a candidate IL-2 mutein of interest in a total volume of 200 ⁇ l.
- a reference IL-2 mutein for example, des-alanyl-1, C125S or C125S human IL-2 mutein, or varying concentrations of a candidate IL-2 mutein of interest in a total volume of 200 ⁇ l.
- the IL-2-stimulated NK3.3 effector cells are co-incubated with 5 x 10 3 calcein AM-labeled target cells (K562 or Daudi) or antibody-coated, calcein AM-labeled targets (Daudi coated with rituximab at a final concentration of 2 ⁇ g/ml) to achieve a final effector-to-target ratio of 10:1.
- the 96 well plates are briefly centrifuged; 100 ⁇ l of culture supernatant is removed and placed into a black, clear, flat- bottom 96-well plate for quantitation of calcein AM release by fluorimeter.
- % specific lysis 100 x [(mean experimental - mean spontaneous release)/(mean maximal release - mean spontaneous release)]; whereby the spontaneous release is determined from wells containing labeled targets and no effectors, and maximal release is determined from wells containing labeled targets and 1% Triton X-100.
- the third IL-2 bioassay disclosed herein provides a method for screening candidate IL-2 muteins for their ability to induce T cell proliferation.
- Kit225 human T-cell line Kit225 (CMCC ID#11234), derived from a patient with T-cell chronic lymphocytic leukemia (Hori et al. (1987) Blood 70(4):1069-1072).
- Kit225 cells constitutively express the ⁇ , ⁇ , ⁇ subunits of the IL-2 receptor complex. Proliferation of Kit225 is IL-2 dependent; cells will die if cultured in the absence of IL-2 for an extended period of time.
- the assay consists of culturing Kit225 cells in the absence of IL-2 for 24 h, followed by plating a specified number of cells with varying concentrations of the reference IL-2 mutein, for example, des-alanyl-1 C125S or C125S human IL-2 mutein, or varying concentrations of a candidate IL-2 mutein of interest. Following a 48-h incubation, proliferation is determined using a standard, commercially available MTT dye reduction kit, and a stimulation index is calculated based on a colorimetric readout.
- the reference IL-2 mutein for example, des-alanyl-1 C125S or C125S human IL-2 mutein, or varying concentrations of a candidate IL-2 mutein of interest.
- the fourth IL-2 bioassay of the present invention provides a method for screening candidate IL-2 muteins for their ability to promote NK cell survival, hi this manner, candidate muteins are screened for their ability to induce NK cell survival signaling.
- Proleukin® IL-2 i.e., the formulation comprising the des-alanyl-1 C125S human IL-2 mutein
- NK3.3 cells are expanded and maintained in RPMI-1640 medium supplemented with 15%, heat- inactivated fetal bovine serum, 25 mM HEPES, 2 mM L-glutamine, and 20% Human T- StimTM w/PHA as a source of IL-2.
- NK3.3 cells are cultured in the absence of IL-2 for 24 h.
- "starved" NK3.3 cells (2 x 10 6 ) are stimulated by addition of 2 nM of the reference IL-2 mutein, for example, the des-alanyl-1 C125S or C125S human IL-2 mutein, or 2 nM of a candidate IL-2 mutein of interest, for 30 min.
- Cells are washed twice in phosphate buffered saline (PBS). The cell pellet is lysed in 50 ⁇ l of a cell extraction buffer containing protease inhibitors and subjected to one freeze-thaw cycle.
- the extract is centrifuged at 13,000 rpm for 10 min @ 4°C. An aliquot of the cleared lysate is added at a 1 :10 dilution to wells of the AKT [pS473]* hnmunoassay Kit (BioSource hitemational). Following the manufacturer's protocol, levels of phosphorylated AKT are detected by quantitative ELISA.
- the present invention also provides bioassays for use in screening IL-2 muteins for their functional profiles using human peripheral blood mononuclear cells (PBMC). The first of these bioassays is a combination proliferation pro-inflammatory cytokine production bioassay.
- PBMC Upon exposure to IL-2, human PBMC proliferate and secrete cytokines in a dose-dependent manner.
- This combination assay was designed to assess levels of proliferation and cytokine production following 72 h stimulation with a reference IL-2 mutein (such as the des-alanyl-1, C125S mutein or C125S mutein) or a candidate IL-2 mutein of interest.
- PBMC are isolated by density gradient separation (for example, using ACDA Vacutainer CPT tubes) from one or more normal human donors.
- IL-2 IL-2
- RPMI complete RPMI medium
- HEPES heat-inactivated human AB serum
- 25 mM HEPES 25 mM HEPES
- 2 mM glutamine penicillin/streptomycin/fungizone
- the cells are pulsed with 1 ⁇ Ci 3 H-thymidine for 6 h, and then harvested to determine levels of nucleotide incorporation (for example, using a Wallac Trilux Microbeta Plate Reader) as a measure of cell proliferation.
- ELISA kits for example, from BioSource International
- ELISA kits can then be used to detect levels of TNF- ⁇ in the cell culture supernatants per manufacturer's guidelines. Repeating the assay for a complete panel of separate donors, for example, 6, 8, or 10 donors, provides a characterization of representative proliferative and cytokine responses to IL-2 in a "normal population.” Data can then be analyzed as shown in Figure 1, and described further herein below in Example 10.
- the second PBMC-based bioassay can be used to screen candidate IL-2 muteins for their ability to mediate effector cell cytotoxicity.
- human PBMC are separated from whole blood using density gradient centrifugation.
- PBMC are stimulated for 3 days in the presence of 10 nM IL-2 control or IL-2 mutein of interest, to generate LAK activity as generally practiced in current state of the art (see for example Isolation of Human NK Cells and Generation of LAK activity IN: Current Protocols in Immunology; 1996 John Wiley & Sons, Inc).
- the resulting cell population contains "effector" cells, which may be classified as NK or LAK, and can kill K562 and Daudi tumor cell targets, respectively.
- effector cells may also mediate ADCC, whereby the effector cells recognize the Fc portion of a specific antibody that is bound to the Daudi target cells.
- the antibody bound to the Daudi target cells is Rituxan® (rituximab).
- human PBMC effector cells
- calcein AM-labeled target cells at various effector to target cell (E:T ratios) for 4 h.
- E:T ratios effector to target cell
- NK natural/spontaneous cytotoxicity
- LAK lymphokine-activated killing
- ADCC antibody-dependent cellular cytotoxicity
- Controls for this bioassay include labeled target cells alone (min) and labeled target cells with final 1% Triton X-100 as a measure of 100%, lysis (max).
- % lysis 100 X mean experimental rfu - mean spontaneous release rfu mean maximal release rfu - mean spontaneous release rfu
- IL-2 mutein to relevant IL-2 reference control (for example, des-alanyl-1, C125S human IL-2 mutein or C125S human IL-2 mutein) can be used to determine whether cytotoxic activity is maintained relative to the IL-2 reference control in a mixed population of hmnan PBMC donors.
- relevant IL-2 reference control for example, des-alanyl-1, C125S human IL-2 mutein or C125S human IL-2 mutein
- the foregoing assays can be utilized to screen candidate IL-2 mutein libraries for desired functional profiles, where the functional activities of interest include one or more of the following: IL-2 induced pro-inflammatory cytokine production (particularly TNF- ⁇ and/or IFN- ⁇ ), IL-2 induced NK and/or T cell proliferation, IL-2 induced NK-mediated cytotoxicity (NK, LAK, and ADCC), and IL-2 induced NK cell survival.
- IL-2 induced pro-inflammatory cytokine production particularly TNF- ⁇ and/or IFN- ⁇
- IL-2 induced NK and/or T cell proliferation IL-2 induced NK-mediated cytotoxicity
- NK, LAK, and ADCC IL-2 induced NK cell survival.
- the therapeutic utility of IL-2 is hampered by the toxicities associated with its administration, including fevers, chills, hypotension, and vascular leak syndrome.
- IL-2 muteins with improved tolerability and IL-2-mediated NK and T effector functions would allow for administration of similar therapeutic doses that are better tolerated of higher therapeutic doses, thereby increasing the potential for greater therapeutic efficacy of this protein.
- the overall strategy of the work presented herein was to select novel human IL- 2 muteins that exhibit the following functional profile using a comprehensive panel of specialized moderate tliroughput human NK cell-based immunoassay screening systems: reduced piO-inflammatory cytokine production (particularly TNF- ⁇ and/or IFN- ⁇ ) so as to improve tolerability, and improved NK cell-mediated function as reflected in the ability of the mutein to maintain or increase NK and/or T cell proliferation, to maintain or increase NK-mediated cytotoxicity (NK, LAK, and ADCC), and to maintain or increase NK cell survival.
- the biological activities of the candidate recombinant human IL-2 muteins were compared to these biological activities exhibited by des-alanyl-1, C125S human IL-2 (abbreviated as "Pro” in the examples below) and C125S human IL-2 (abbreviated as "Ala-Pro” in the examples below), which are referred to as the reference IL-2 muteins.
- the recombinantly E. c ⁇ /z ' -produced des-alanyl-1, C125S human IL-2 mutein, which is aldesleukin, is marketed as a formulation under the tradename Proleukin® IL-2 (Chiron Corporation, Emeryville, California).
- Proleukin® IL-2 is a specific lyophilized formulation that uses an unglycosylated form of the mutein that has been produced in E. coli, and was reconstituted in distilled water for use in the bioassays described herein below.
- a monomeric formulation of aldesleukin marketed under the tradename L2-7001® IL-2 (Chiron) is used, which is a liquid formulation comprising the same human IL-2 mutein (aldesleukin) as Proleukin® IL-2, but differing in the final purification steps prior to its formulation. See U.S. Pat. No. 4,931,543 and U.S. Pat. No. 6,525,102.
- the C125S human IL-2 used in the initial screening experiments was produced in the AME mammalian system, and was formulated in proprietary AME buffer.
- the human IL-muteins described herein below were expressed in host mammalian 293T cells. Where the reference IL-2 mutein was C125S human IL-2, the host cells had been transformed with an expression construct comprising the native human IL-2 coding sequence with a C125S mutation operably linked to the Pro-1 promoter.
- the coding sequence comprised the authentic IL-2 signal sequence and codon for the N-terminal alanine of human IL-2 (i.e., nucleotides 1-63 of SEQ ID NO:l) fused at the coding sequence for des-alanyl-1, C125S human IL-2 (i.e., SEQ ID NO:7).
- the protein was expressed as GSHis-tagged protein in the 293T cell mammalian expression system and purified with NI-NTA beads.
- Example 1 Initial Screening of Human IL-2 Muteins A library comprising all 2,508 possible single amino acid mutein variants of the
- Ala-Pro differs from the des-alanyl-1 C125S human IL-2 mutein utilized in the commercially available Proleukin® IL-2 product in having the N-terminal Ala residue at position 1 of the native human IL-2 sequence retained in the C125S human IL-2 mutein.
- the AME mammalian expression systems DirectAMETM and ExpressAMETM were utilized in the recombinant production of the Ala-Pro muteins.
- the primary screen was carried out using a human NK-92 cell line-based functional immunoassay, in which pro-inflammatory cytokine production (TNF- ⁇ ), NK cell proliferation, and NK cytolytic killing (NK, LAK, and ADCC), and cell survival (pAKT; NK3.3 cell line) were assayed.
- TNF- ⁇ pro-inflammatory cytokine production
- NK cell proliferation NK cell proliferation
- NK cytolytic killing NK, LAK, and ADCC
- pAKT cell survival
- Ala-Pro IL-2 i.e., C125S human IL-2 mutein
- Proleukin®IL-2 i.e., des-alanyl-1, C125S human IL-2 mutein
- IL-2 muteins selected maintain NK cytolytic function (NK/LAK/ADCC) when compared to the des-alanyl-1, C125S (i.e., present in Proleukin® IL-2) or C125S (i.e., Ala-Pro) human IL-2 muteins.
- the first class of muteins is predicted to have improved tolerability as evidenced by decreased induction of TNF- ⁇ production by NK cells relative to that observed with the des-alanyl-1 C125S human IL-2 mutein or C125S human IL-2 mutein.
- the muteins within this class fall within two categories: (1) those that induce low TNF- ⁇ production and maintain NK cell proliferation at concentrations of 50 pM to 1000 pM, which include the des-alanyl-1, C125S or C125S human IL-2 muteins further comprising the L72N substitution; and (2) those that induce low TNF- ⁇ production and maintain proliferation at high concentration (1 nM) only, which include the des-alanyl-1 C125S or C125S human IL-2 muteins further comprising the V91D or F42E substitution. See Example 8 and Tables 13 and 14, below.
- the second class of muteins includes those that were identified as having increased NK cell function, particularly NK cell proliferation, relative to that observed with des-alanyl-1, C125S human IL-2 mutein (i.e., in Proleukin® IL-2) or the C125S human IL-2 mutein (designated Ala-Pro IL-2 herein).
- Muteins identified within this functional class include the des-alanyl-1, C125S or C125S human IL-2 muteins further comprising the L36D and L40D substitution. See Example 8 and Table 15, below.
- the third class of muteins includes "bifunctional" muteins that are predicted to have improved tolerability based on the decreased induction of TNF- ⁇ while also increasing NK proliferation relative to that observed with the des-alanyl-1, C125S human IL-2 mutein present in Proleukin® IL-2 or the C125S human IL-2 mutein (designated Ala-Pro IL-2 herein). These "bifunctional" muteins exhibit an improved ratio of NK proliferation:TNF- ⁇ production of greater than 1.5.
- Muteins identified within this functional class include the des-alanyl-1, C125S or C125S human IL-2 muteins further comprising the L19D, F42R, or E61R substitution. See Example 8 and Table 16, below. The screening process that led to the identification of the leading candidates fitting into these three functional classes is further described in the examples below. The following protocols were used in the screening process.
- NK Cell Proliferation/TNF-a Production utilizes the human NK-92 cell line (ATCC CRL-2407, CMCC ID #11925).
- the NK-92 cell line originally described by Gong et al (1994) Leukemia 8(4):652-658, displays phenotypic and functional characteristics of activated NK cells. Proliferation of NK-92 is IL-2 dependent; cells will die if cultured in the absence of IL-2 for 72 hours. The cell line also produces detectable levels of TNF- ⁇ within 48-72 hours following exposure to IL-2.
- NK-92 cells were cultured in complete medium (NK-92 medium) consisting of Alpha-MEM, 12% heat-inactivated fetal bovine serum (FBS), 8%, heat-inactivated horse serum, 0.02 mM folic acid, 0.2 mM inositol, 2 mM L-glutamine, and 0.1 mM ⁇ - mercaptoethanol.
- NK-92 medium consisting of Alpha-MEM, 12% heat-inactivated fetal bovine serum (FBS), 8%, heat-inactivated horse serum, 0.02 mM folic acid, 0.2 mM inositol, 2 mM L-glutamine, and 0.1 mM ⁇ - mercaptoethanol.
- Cultures were seeded at a minimum density of 1-3 x 10 5 cells/ml and supplemented with 1000 IU/ml recombinant human IL-2 mutein (des-alanyl-1, C125S human IL-2 (i.e., aldesleukin or Proleukin® IL-2; Chiron Corporation, Emeryville, California) or C125S human IL-2 (recombinantly produced in the AME's mammalian expression system noted above).
- human IL-2 mutein des-alanyl-1, C125S human IL-2 (i.e., aldesleukin or Proleukin® IL-2; Chiron Corporation, Emeryville, California) or C125S human IL-2 (recombinantly produced in the AME's mammalian expression system noted above).
- NK-92 were placed in fresh NK-92 medium a minimum of 48 h prior to assay use.
- NK-92 were washed three times and placed in NK-92 medium without
- TNF- ⁇ ELISA kit BioSource CytoscreenTM Human TNF- ⁇ ELISA kit; Camarillo, California.
- proliferation was determined using a commercially available MTT dye-reduction kit (CellTiter 96® Non- Radioactive Cell Proliferation Assay Kit (Promega Corp., Madison, Wisconsin), and a stimulation index was then calculated based on a colorimetric readout.
- the IL-2 bioassay for natural killer (NK) cell-mediated cytotoxicity utilizes the human NK3.3 cell line.
- the NK3.3 cell line displays phenotypic and functional characteristics of peripheral blood NK cells ( Kombluth (1982) J Immunol. 129(6):2831- 2837), and can mediate antibody-dependent cellular cytotoxicity (ADCC) via the Fc receptor (CD16, Fc ⁇ RIIIA).
- the cell line was obtained from Jackie Kombluth, Ph.D., under limited use license agreement with St. Louis University, and deposited to CMCC (ID 12022).
- Table 2 summarizes the biological activities of NK3.3 cells examined with this IL-2 bioassay.
- NK3.3 cells were expanded and maintained in RPMI- 1640 medium supplemented with 15%) heat-inactivated fetal bovine serum, 25 mM HEPES, 2 mM L-glutamine, and 20% Human T-StimTM w/PHA as a source of IL-2. hi preparation for the assay, NK3.3 cells were cultured in the absence of IL-2 ("starved) for 24 h.
- the assay consists of 5 x 10 4 "starved" NK3.3 cells plated in U-bottom 96-well plates, exposed to varying concentrations of des-alanyl-1, C125S or C125S human IL-2 as the reference IL-2 molecule or varying concentrations of an IL-2 mutein of the invention in a total volume of 200 ⁇ l.
- the IL-2-stimulated NK3.3 effector cells were co-incubated with 5 x 10 3 calcein AM-labeled target cells (K562 or Daudi) or antibody- coated, calcein AM-labeled targets (Daudi coated with rituximab at a final concentration of 2 ⁇ g/ml) to achieve a final effector-to-target ratio of 10:1.
- the 96 well plates were briefly centrifuged; 100 ⁇ l of culture supernatant was removed and placed into a black, clear, flat-bottom 96-well plate for quantitation of calcein AM release by fluorimeter.
- % specific lysis 100 x [(mean experimental - mean spontaneous release)/(mean maximal release - mean spontaneous release)]; whereby the spontaneous release was determined from wells containing labeled targets and no effectors, and maximal release was determined from wells containing labeled targets and 1 %> Triton X- 100.
- T-Cell Proliferation utilizes the human T-cell line Kit225 (CMCC ID#11234), derived from a patient with T-cell chronic lymphocytic leukemia
- Kit 225 cells constitutively express the ⁇ , ⁇ , ⁇ subunits of the IL-2 receptor complex. Proliferation of Kit225 is IL-2 dependent; cells will die if cultured in the absence of IL-2 for an extended period of time.
- the assay consists of Kit225 cells, cultured in the absence of IL-2 for 24 h, followed by plating a specified number of cells with varying concentrations of des-alanyl- 1 C125S or C125S human IL-2 as the reference IL-2 molecule or varying concentrations of an IL-2 mutein of the invention.
- NK Cell Survival Signaling A subset of the human IL-2 mutein library was screened for the ability to induce
- NK cell survival signaling Proleukin® IL-2 (i.e., aldesleukin, the des-alanyl-1 C125S human IL-2 mutein) induces the phosphorylation of AKT in NK3.3 cells previously starved for IL-2, which is considered a "survival signal.”
- NK3.3 cells were expanded and maintained in RPMI- 1640 medium supplemented with 15%, heat-inactivated fetal bovine serum, 25 mM HEPES, 2 mM L-glutamine, and 20% Human T-StimTM w/PHA as a source of IL-2.
- NK3.3 cells were cultured in the absence of IL-2 for 24 h.
- NK3.3 cells (2 x 10 6 ) were stimulated by addition of 2 nM of des-alanyl-1 C125S or C125S human IL-2 as the reference IL-2 molecule or 2 nM of an IL-2 mutein of the invention, for 30 min.
- Cells were washed twice in phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- the cell pellet was lysed in 50 ⁇ l of a cell extraction buffer containing protease inhibitors and subjected to one freeze-thaw cycle.
- the extract was centrifuged at 13,000 rpm for 10 min @ 4°C.
- Total TNP- ⁇ production (pg/ml) at 1.0 nM protein and TNF- ⁇ production as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro) are shown.
- CPA values are expressed as a percentage of that observed for des-alanyl-, 1 C125S human IL-2 (%Pro).
- the ratio of %NK cell proliferation at 0.1 nM protein relative to %TNF- ⁇ production at 1.0 nM protein is shown (%CPA 0.1 :TNF- ).
- Cytotoxicity assay values are expressed as a ratio of the values observed for des-alanyl-1, C125S human IL-2 (-.Pro) or for C125S human IL-2 (: Ala-Pro).
- This analysis identified 4 additional mutations, all occurring at key positions 36, 40, and 65, in which the mutein induced NK cell proliferation greater than 150%> of that mediated by the des-alanyl-1, C125S human IL-2 mutein (i.e., present in Proleukin® IL-2) at 0.1 nM, and induced TNF- ⁇ production at 1 nM that was ⁇ 100%, of that mediated by a similar amount of the des-alanyl-1 C125S human IL-2 mutein (i.e., 1 nM).
- This secondary analysis also identified 7 additional mutations, all occurring at key positions 36, 64, and 65, as eliciting slight increases in TNF- ⁇ production at 1 nM (about 101-109%, of that observed with a similar amount of the des-alanyl-1, C125S human IL-2 reference molecule) while still inducing NK cell proliferation greater than 150% of that mediated by the des-alanyl-1, C125S human IL-2 mutein at 0.1 nM. TNF-alpha production. See Table 4.
- Muteins were selected that elicited less than 87%, of the TNF- ⁇ production of des- alanyl-1, C125S (i.e., mutein present in Proleukin® IL-2) or C125S human IL-2 mutein IL-2 (designated Ala-Pro IL-2), each at 1 nM, and that maintained (at least 96.4%) or enlianced NK cell proliferation as compared to des-alanyl-1, C125S human IL-2 at both 0.1 nM and 1 nM, and that maintained (at least 79.2%>) NK cell proliferation relative to the C125S human IL-2 mutein at 0.1 nM (data not shown). See Table 5.
- IL-2 muteins identified using the following selection criteria TNF- ⁇ production ⁇ 87% of that observed for des-alanyl-1, C125S human IL-2 (Pro) at 1.0 nM and NK cell proliferation at two concentrations ( 0.1 and 1.0 nM) maintained or improved relative to that observed for des-alanyl-1, C125S human IL-2 (Pro).
- Total TNF- ⁇ production (pg/ml) at 1.0 nM and TNF- ⁇ production as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro) or C125S human IL-2 (%Ala-Pro) are shown.
- CPA values are expressed as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro).
- the ratio of % NK cell proliferation at 0.1 nM protein relative to %TNF- ⁇ production at l.O nM protem is shown (%CPA 0.1 :TNF- ⁇ ).
- Cytotoxicity assay values are expressed as a ratio of the values observed for des-alanyl-1, C125S human IL-2 (:Pro) or for C125S human IL-2 (:Ala-Pro).
- screening criteria were adjusted to capture those muteins that met the criteria for TNF- ⁇ production less than 81%, of that stimulated by des-alanyl-1, C125S or C125S human IL-2, each at 1 nM, and that maintained or enhanced NK cell proliferation (at least 95%,) relative to des-alanyl-1, C125S human IL-2 at 1 nM (i.e., only at a single concentration of the reference IL-2 mutein).
- These screening criteria identified additional muteins that involved residue changes at positions 20, 78, 79, 80, 81, 88, and 126. See Table 6.
- IL-2 muteins identified using the following selection criteria: TNF- ⁇ production ⁇ 81% of that observed for des-alanyl-1, C125S human IL-2 (Pro), each at 1.0 nM, and NK cell proliferation at 1.0 nM maintained or improved relative to des-alanyl-1, C125S human IL-2 mutein (Pro).
- Total TNF- ⁇ production (pg/ml) at 1.0 nM and TNF- ⁇ production as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro) or C125S human IL-2 (%Ala-Pro) are shown.
- CPA values are expressed as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro).
- %NK cell proliferation at 0.1 nM protein The ratio of %NK cell proliferation at 0.1 nM protein relative to %TNF- ⁇ production at 1.0 nM protein is shown (%CPA 0.1:TNF- ⁇ ). Cytotoxicity assay values are expressed as a ratio of the values observed for des-alanyl-1, C125S human IL-2 (:Pro) or for C125S human IL-2 (:Ala-Pro).
- IL-2 muteins identified using the following selection criteria: TNF- ⁇ production ⁇ 96.2% of that observed for des-alanyl-1, C125S human IL-2 (Pro), each at 1.0 nM, and NK cell proliferation at 1.0 nM maintained or improved relative to des-alanyl-1, C125S human IL-2 (Pro).
- Total TNF- ⁇ production (pg/ml) at 1.0 nM and TNF- ⁇ production as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro) or C125S human IL-2 (% Ala-Pro) are shown.
- CPA values are expressed as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro).
- %CPA 0.1 :TNF- ⁇ The ratio of % NK cell proliferation at 0.1 nM protein relative to %TNF- ⁇ production at 1.0 nM protein is shown (%CPA 0.1 :TNF- ⁇ ). Cytotoxicity assay values are expressed as a ratio of the values observed for des-alanyl-I, C125S human IL-2 (:Pro) or for C125S human IL-2 (:Ala-Pro).
- Example 4 Identification of IL-2 Muteins with Enhanced NK-Mediated Cytotoxicity Muteins were selected that enhanced NK-mediated cytotoxicity against K562 cells at least 140% over that of the C125S human IL-2 mutein (i.e., Ala-Pro) and at least 115%) over that of the des-alanyl-1 C125S human IL-2 mutein (i.e., mutein present in Proleukin® IL-2) when assayed at either 0.1 nM or 1.0 nM, as well as eliciting less than 100%) of the TNF- ⁇ production exhibited by either of these two reference IL-2 muteins when assayed at 1 nM, and maintaining NK cell proliferation (at least 100%>) relative to these two reference IL-2 muteins when assayed at 0.1 nM or 1 nM. See Table 8.
- LL-2 mutein natural cytotoxicity muteins identified using NK3.3 cytotoxicity assay (K562 targets).
- Total TNF- ⁇ production (pg/ml) at 1.0 nM and TNF- ⁇ production as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro) or C125S human LL-2 (%Ala-Pro) are shown.
- CPA values are expressed as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro) or C125S human IL-2 (%Ala-Pro) at 0.1 nM or 1 nM.
- %N cell proliferation at 0.1 nM protein The ratio of %N cell proliferation at 0.1 nM protein relative to %TNF- ⁇ production at 1.0 nM protein is shown for the Pro (%CPA:TNF- ⁇ (Pro)) and Ala-Pro (%CPA:TNF- ⁇ (Ala-Pro)). Cytotoxicity assay values are expressed as a ratio of the values observed for des-alanyl-1, C125S human LL-2 (:Pro) or for C125S human IL-2 (Ala-
- Muteins were then selected based on the following critera: enhanced NK cell-mediated LAK activity to greater than 120%> that of the C125S human IL-2 mutein (i.e., Ala-Pro) and maintained (at least 100%,) NK cell-mediated LAK activity relative to the des-alanyl-1, C125S human IL-2 mutein present in Proleukin® LL-2, as well as eliciting less than 100% the TNF- ⁇ of both the des- alanyl-1, C125S human IL-2 mutein and the C125S human IL-2 mutein at InM and maintaining NK cell proliferation (at least 100%>) compared to both of these reference IL-2 muteins at both 0. InM and InM. See Table 9.
- LL-2 mutein lymphokine activated killer (LAK) activity hits identified using NK3.3 cytotoxicity assay (Daudi targets).
- Total TNF- ⁇ production (pg/ml) and TNF- ⁇ production as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro) or C125S human IL-2 (%Ala-Pro) are shown for each individual mutein.
- CPA values are expressed as a percentage of that observed for des-alanyl- 1,C125 S human IL 2 (%Pro) or C125S human IL-2 (%Ala-Pro) at 0.1 nM or 1 nM.
- %CPA:TNF- ⁇ (Pro) The ratio of % NK cell proliferation at 0.1 nM protein relative to %TNF- ⁇ production at 1.0 nM protein is shown for the Pro (%CPA:TNF- ⁇ (Pro)) and Ala-Pro (%CPA:TNF- ⁇ (Ala-Pro)). Cytotoxicity assay values are expressed as a ratio of the values observed for des-alanyl-1, C125S human LL-2 (:Pro) or for C125S human IL-2 (:Ala-Pro).
- Muteins were then selected based on the criteria of having enhanced NK cell- mediated ADCC activity at least 115% that of the C125S human IL-2 mutein (Ala-Pro) and at least 105% that of the des-alanyl-1, C125S human IL-2 mutein (Pro), and that elicited less than 100%, the TNF- ⁇ of both of the reference IL-2 muteins, each at InM, and maintained NK cell proliferation (at least 100%) compared to both of the reference IL-2 muteins, each at O.lnM. See Table 10.
- Total TNF- ⁇ production (pg/ml) and TNF- ⁇ production as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%>Pro) or C125S human IL-2 (% Ala-Pro) are shown.
- CPA values are expressed as a percentage of that observed for des-alanyl-1, C125S human IL-2 (%Pro).
- the ratio of %NK cell proliferation at 0.1 nM protein relative to %TNF- ⁇ production at 1.0 nM protein is shown (%CPA:TNF- ⁇ ).
- Cytotoxicity assay values are expressed as a ratio of the values observed for des-alanyl-1, C125S human IL-2 (:Pro) or for C125S human IL-2 (:Ala-Pro).
- Example 7 Selection of Muteins Supporting Enhanced NK Cell Survival Muteins were screened for their ability to enhance NK cell survival as compared to the des-alanyl-1, C125S human IL-2 mutein. See Table 11.
- Example 8 Selection of Human IL-2 Muteins with Most Improved Therapeutic Profile Using the selection criteria described above, twenty-five human IL-2 muteins were identified as being of particular interest. These muteins are shown in Table 12.
- the muteins were further divided into groups that satisfied the following selection criteria: 1) muteins that exhibit TNF- ⁇ production ⁇ 80%> of that observed for the C125S human IL-2 mutein and that: a) maintain proliferation at 1 nM, but relative to the reference IL-2 mutein, proliferative activity drops at lower concentrations, which includes the des- alanyl-1, C125S human IL-2 mutein or the C125S human IL-2 mutein further comprising the F42E or V91D mutation (see Table 13); or, b) exhibit significant decreases in TNF- ⁇ production at 1 nM, and where proliferative activity is maintained down to 50 pM, which includes the des-alanyl- 1, C125S human IL-2 mutein or the C125S human IL-2 mutein further comprising the L72N mutation (see Table 14); 2) muteins that augment NK-92 proliferation >200% compared to C125S human IL
- selection criteria included a proliferation index greater than 150%) of that observed for the reference IL-2 mutein, i.e., C125S human IL-2 (Ala- Pro) for at least 2 concentrations tested; this group includes the des-alanyl-1, C125S human IL-2 mutein or the C125S human IL-2 mutein further comprising the L36D or L40D mutation (see Table 15); and, 3) muteins that showed increased proliferative activity and decreased TNF- ⁇ production, where TNF- ⁇ production is ⁇ 15% of that observed for the C125S human IL- 2 mutein when tested at InM, and proliferation of NK cells is >150% of that observed for the C125S human IL-2 mutein at any one concentration tested (5 pM, 20 pM, 50 pM, 100 pM, and 1000 pM); this group includes the des-alanyl-1, C125S human IL-2 mutein or the C125S human IL-2 mutein further comprising the L19D
- IL-2 muteins identified within the bifunctional series increased NK proliferation and decreased TNF- ⁇ relative to C125S human IL-2 mutein.
- Example 9 Human IL-2 Muteins Maintain T Cell Proliferation
- a secondary functional endpoint serving as a basis of selecting beneficial mutations was maintained or improved T cell proliferation by the human Kit225 T cell line relative to that observed with Ala-Pro IL-2 (i.e., C25S human IL-2 mutein) or Proleukin® (i.e., des-alanyl-1, C125S human IL-2 mutein).
- Ala-Pro IL-2 i.e., C25S human IL-2 mutein
- Proleukin® i.e., des-alanyl-1, C125S human IL-2 mutein
- Example 10 Identification of Beneficial IL-2 Mutations that Reduce Pro-inflammatory Cytokine Production while Maintaining or Increasing Levels of Proliferation and Cytotoxicity in Normal Human Peripheral Blood Mononuclear Cells
- IL-2 muteins were selected for a small-scale expression purification as indicated in Table 18. These IL-2 muteins were tested for their ability to generate a similar functional profile of increased tolerability and maintained activity in peripheral blood mononuclear cells (PBMC) isolated from several normal human blood donors, as compared to relevant IL-2 controls (des-alanyl-1, C125S human IL-2 mutein (present in Proleukin®) and yeast- expressed C125S human IL-2 mutein (designated Y-Pro in the data herein).
- PBMC peripheral blood mononuclear cells
- human PBMC derived from a panel of normal human donors were stimulated with the IL-2 mutein of interest, and assayed for proliferation and pro-inflammatory cytokine production (TNF- ⁇ ), as well as the ability to kill tumor cell targets by natural/spontaneous cytotoxicity (NK), lymphokine-activated killing (LAK), or antibody dependent cellular cytotoxicity (ADCC).
- TNF- ⁇ pro-inflammatory cytokine production
- NK natural/spontaneous cytotoxicity
- LAK lymphokine-activated killing
- ADCC antibody dependent cellular cytotoxicity
- IL-2 muteins identified by: amino acid position relative to mature human IL-2 of SEQ ID NO:4, and amino acid substitution at that position.
- the following primary functional endpoints were used: 1) Reduced pro-inflammatory cytokine production (TNF- ⁇ ) by human PBMC stimulated with IL-2 mutein as compared to relevant human IL-2 mutein control. 2) Maintained or improved IL-2 induced proliferation in human PBMC without an increase in pro-inflammatory cytokine production as compared to relevant human IL-2 mutein control 3) Maintained or improved NK, LAK, and ADCC mediated cytolytic killing by human PBMC stimulated in vitro with IL-2 mutein as compared to relevant human IL-2 mutein control.
- Combination Proliferation/Proinflammator ⁇ Cytokine Production Assay Procedure Upon exposure to IL-2, human PBMC proliferate and secrete cytokines in a dose- dependent manner. To maximize data output and efficiency, a combination assay was designed to assess levels of proliferation and cytokine production following 72 h stimulation with the reference IL-2 mutein or the human IL-2 mutein of interest.
- the assay setup involves isolation of PBMC by density gradient separation (ACDA Vacutainer CPT tubes) from one or more normal human donors.
- IL-2 IL-2
- RPMI complete RPMI medium
- HEPES heat-inactivated human AB serum
- 25 mM HEPES 25 mM HEPES
- 2 mM glutamine penicillin/streptomycin/fungizone
- the cells are pulsed with 1 ⁇ Ci 3 H-thymidine for 6 h then harvested to determine levels of nucleotide incorporation (Wallac Trilux Microbeta Plate Reader) as a measure of cell proliferation.
- Wallac Trilux Microbeta Plate Reader Commercially available ELISA kits (BioSource International) were used to detect levels of TNF- ⁇ in the cell culture supernatants per manufacturer's guidelines. Repeating the assay for a complete panel of six separate donors provides a characterization of representative proliferative and cytokine responses to IL-2 in a "normal population.”
- PBMC samples were plated in duplicate in separate assay plates to assess reproducibility. Proliferation data was analyzed by subtracting background proliferation (PBMC + no IL-2) and means of duplicate samples calculated. Cytokine data was derived from cell culture supernatants removed from assay wells containing PBMC and pooled to obtain the mean cytokine level in the duplicate set up. TNF- ⁇ levels were quantitated at pg/ml, based on a standard curve of purified TNF- ⁇ contained in the ELISA kit. Data were further compiled for the panel of six normal human donors as outlined in the schematic shown in Figure 1.
- PBMC are separated from whole blood using density gradient centrifugation. PBMC are stimulated for 3 days in the presence of 10 nM IL-2 control or IL-2 mutein of interest, to generate LAK activity as generally practiced in current state of the art (see for example Isolation of Human NK Cells and Generation of LAK activity IN: Current Protocols in Immunology; 1996 John Wiley & Sons, fric).
- the resulting cell population contains "effector" cells, which may be classified as NK or LAK, and can kill K562 and Daudi tumor cell targets, respectively. These effector cells may also mediate ADCC, whereby the effector cells recognize the Fc portion of a specific antibody (in this case Rituxan®) that is bound to the Daudi target cells.
- a specific antibody in this case Rituxan®
- the assay involves co-incubation of effector cells with calcein AM-labeled target cells at various effector to target cell (E:T ratios) for 4 h.
- the amount of cytotoxic activity is related to the detection of calcein AM in the culture supernatant. Quantitation is expressed as percent specific lysis at each E:T ratio, based upon determination of spontaneous and maximum release controls.
- the assay examines the following biological activities:
- Controls include labeled target cells alone (min) and labeled target cells with final 1% Triton X-100 as a measure of 100% lysis (max).
- the percent min to max ratio is calculated using the following equation as a measure of assay validity (assay invalid if >
- % lysis 100 X mean experimental rfu - mean spontaneous release rfu mean maximal release rfu — mean spontaneous release rfu Data is reported as % specific lysis; in addition the ratio of IL-2 mutein to relevant IL-2 control was used to determine whether cytotoxic activity was maintained relative to control IL-2 in a mixed population of human PBMC donors.
- IL-2 muteins Five beneficial IL-2 mutations that reduce pro-inflammatory cytokine production while maintaining or increasing levels of proliferation and cytotoxicity in normal human PBMC were identified.
- IL-2 muteins were tested along with the relevant control, i.e., des-alanyl-1, C125S human IL-2 expressed and purified in the same yeast system (designated Y-Pro). Initially IL-2 muteins were tested in the combination proliferation/pro-imTammatory cytokine production assay over a dose response curve (39 pM - 10 nM) in two independent assay setups, each with three normal blood donor PBMC tested in duplicate.
- Values represent average percent decrease from Y-Pro control from panel of 6 normal human PBMC donors. Cytokine data was normalized to proliferation.
- mice were implanted intravenously with B16F10 melanoma cells (50,0000 cells/mouse) on day one of the study. Mice were 4-6 weeks old and randomized into groups of ten based on body weight. All groups had mean body weights within 20%) of one another. Treatments were administered to mice on day two and consisted of IL-2 in the form of Proleukin®, RL-2 (research grade IL-2 from E.
- Proleukin®, RL-2, L2-7001®, and the IL-2 muteins, E95D and Y107R were administered thrice weekly intravenously in murine B 16F10 melanoma lung metastases models in C57BL/6 mice ( Figures 8 and 9).
- the minimum effective dose (MED) of the IL-2 test agents dose that was statistically significant vs. the pharmaceutical vehicle) were as follows: Proleukin® (3.3 mg/kg), L2-7001® (3.3 mg/kg), RL-2 (3.3 mg/kg), E95D (5.7 mg/kg), and Y107R (5.7 mg/kg).
- the ED50's (50% inhibition of metastases compared to pharmaceutical vehicle) of test agents were 2.4 mg/kg for L2-7001®, 4.8 mg/kg for E95D, and 6.1 mg/kg for Y107R.
- Y107R and E95D dosed at 5.7 mg/kg (3x/wk) produced equivalent inhibition of metastases compared to IL-2 benchmarks (Proleukin®, L2-7001).
- the maximum tolerated dose (MTD) was not reached for muteins or L2-7001®. All doses of test agents were well tolerated, and mice exhibited normal body weights throughout the study duration (Figure 9). See Table 20 below, which provides a summary of efficacy results.
- IL-2 agents were then tested using the "Sleijfer" dosage regimen (5 days on/2 days off/5 days on).
- E95D and Y107R at all doses showed significant reduction in the mean number of lung metastases compared to vehicle-treated or untreated mice (pO.OOl A ⁇ ONA/Student- ⁇ ewman-Keurs test), and efficacy was equivalent to IL-2 benchmarks (Proleukin®, L2-7001®) ( Figures 10 and 11).
- Y107R at 3.3 and 8.1 mg/kg demonstrated 2/10 and 1/10 of a complete response (CR), respectively (Table 21), where a CR is defined as the complete disappearance of tumors (including microscopic lesions) in the mouse lung.
- the minimum effective dose was 5.7 mg/kg for L2-7001 , F42E and Yl 07R, and the computed ED50' s were 6.47 mg/kg for F42E, 6.33 mg/kg for Y107R, and 5.37 mg/kg for L2-7001.
- test agents Proleukin®, L2-7001®, F42E and Y107R
- IL-2 muteins demonstrated equivalent activity compared to benchmarks, Proleukin® and L2-7001®.
- Doses of 5.7 mg/kg Proleukin® and 10.5 mg/kg L2-7001® exhibited mouse body weight loss and were identified as MTD doses of each agent, respectively (Figure 13).
- E95D, Y107R and F42E IL-2 muteins retain antitumor activity in vivo.
- the efficacy of the E95D, Yl 07R, and F42E IL-2 muteins in the classical B 16 melanoma metastases model is equivalent to benchmarks Proleukin® or L2-7001® at similar doses when administered thrice weekly or according to the "Sleijfer" regimen.
- -I l l- 3 The Y107R and F42E IL-2 muteins are better tolerated than IL-2 benchmarks Proleukin® and L2-7001®, retain IL-2 activity, and demonstrate a superior therapeutic index.
- IL-2 muteins were evaluated in two distinct non-Hodgkin's lymphoma (NHL) models, i.e., Namalwa (high grade NHL) model which is sensitive to IL-2 and the Daudi model (low grade NHL, CD20+), which displays marginal activity with IL-2; but is responsive to rituximab.
- NHL non-Hodgkin's lymphoma
- mice were acclimated for 1 week prior to inoculation with either Namalwa or Daudi cells.
- Namalwa or Daudi cells (5 xlO 6 cells/mouse) were implanted subcutaneously in the right flank of irradiated young nude mice (3Gy ⁇ 3.2 mins) with 50% matrigel at a volume of 0.1 mL. Treatment began when the average tumor volume was 100-200mm 3 . This was designated as day 1 of the study. Tumor volumes and body weight measurements were evaluated twice a week. Clinical observations were noted. Individual mice with tumor volumes greater than 3000 mm 3 or groups with mean tumor volumes greater than 2000 mm were euthanized. Mice with body weight loss greater than 20%, were also sacrificed.
- Endpoints were tumor volume measurements, body weights and clinical observations.
- the efficacies of thrice weekly regimens of Proleukin®, L2-7001®, muteins Y107R or E95D were evaluated in a staged, aggressive human NHL model (Namalwa) in irradiated Balb/c nude mice ( Figures 14-16).
- Single agent L2-7001® showed a good dose-response effect with a calculated ED50 of 2 mg kg (Fig. 16).
- Treatment with Y107R and E95D at 1 mg/kg, 3 times per week demonstrates equivalent activity to benchmarks Proleukin® and L2-7001® at lmg/kg, 3 times per week (p>0.05) in the Namalwa model.
- the muteins were tested up to 3 mg/kg and the MTDs were not reached.
- Proleukin®, L2-7001®, or the IL-2 mutein Y107R with rituximab in a CD20+ low grade human NHL Daudi xenografts in Balb/c nude mice were evaluated ( Figures 17-20).
- the objective of these experiments was to evaluate the role of in vivo activation of effector cells (NK, monocytes, macrophages, neutrophils) on the efficacy of combination therapy with IL-2 and therapeutic antibodies (rituximab).
- Inhibition of tumor growth by treatment with single agents, Proleukin®, L2-7001®, or Y107R, at 3mg/kg is not statistically different from treatment with vehicle (p>0.05, ANOVA day 26) (Figure 17).
- IL-2 muteins may be effective as a single agent in subset cancer populations, including melanoma, NHL.
- Activity of the IL-2 mutein Y107R is marginal against low grade B-cell NHL Daudi model, but is capable of activating immune effector cells (i.e., NK, monocytes, macrophages, neutrophils) to potently mediate ADCC when combined with rituximab
- immune effector cells i.e., NK, monocytes, macrophages, neutrophils
- the IL-2 mutein Y107R and rituximab in combination therapy demonstrate superior efficacy compared to single agents IL-2 or rituximab alone.
- Activity of IL-2 muteins could be applicable to combinations with other antibodies that mediate effects through ADCC or similar immune cell effector mechanims.
- mice Female C57BL/6 mice were acclimated for 1 week prior to the start of the study. Mice were 8-10 weeks old and randomized into groups of five based on body weight. Proleukin®, L2-701®, or an IL-2 mutein, E95D or Y107R, was injected intraperitoneally (i.p.) at 6 mg/kg ( ⁇ 2,000,000 IU), 3 times per day. Injections were repeated for 10 doses. 125 I-albumin (l ⁇ Ci, PerkinElmer Life Sciences Inc. Boston, MA) in 0.1 ml PBS containing 1%, mouse serum was injected 4 hours after the Proleukin® dose on day 4. Mice were euthanized 60 minutes after the injection with 125 I-albumin. The lungs were harvested and placed in a vial for gamma counting.
- Proleukin®, L2-701®, or an IL-2 mutein, E95D or Y107R was injected intraperitoneally (i.p.) at 6
- Example 14 Evaluation of Tolerability of IL-2 Muteins by Monitoring Body Temperature Changes Using a Temperature Chip Introduction
- IL-2 induced natural killer cells NK
- cytokines including IFN- ⁇ , TNF- ⁇ , TNF- ⁇ , IL-l ⁇ , and IL-6 that activate monocytes/macrophages and induce nitric oxide (NO) production leading to subsequent damage of endothelial cells
- NO nitric oxide
- Fever and chills are common Grade 3 adverse events during IL-2 therapy.
- Fever is a physiological reaction to TNF- ⁇ inducing prostaglandm E2 and the onset of fever induces vasoconstriction and shivering preceding the actual change in core temperature.
- IL-2 does not directly induce prostaglandm E2 synthesis in vitro; therefore IL-2 itself is classified as a non-pyrogenic cytokine.
- IL-2 induces the release of pyrogenic cytokines, particularly TNF- ⁇ , a major cause of fever and other aspects of acute phase response during IL-2 therapy (Mier, et al. (1988) J. Clin. Immunol.
- Proleukin®, L2-701®, or an IL-2 mutein, E95D, Y107R, L94Y, or F42E were administered subcutaneously using the "Sleijfer" dosage regimen (5 days on/2 days off/5 days on).
- the body temperatures of mice were monitored at given time points before and after administration of IL-2 and compared to mice injected with a buffer control (vehicle). Endpoints were core body temperature, clinical observations, body weight, and plasma pro-inflammatory cytokine (e.g., TNF- ⁇ ) levels.
- the L2-7001 formulation is better tolerated in the mouse model, as significant temperature drops are consistently observed at doses equal or greater than 8.1 mg/kg, whereas 5.7 mg/kg of Proleukin® is the maximum tolerated dose in this model.
- These observations are consistent with other preclinical models, which dosed for prolonged periods of time (generally 2 week dosing cycles) in tumor-bearing animals.
- Two of the IL-2 muteins, Y107R and F42E showed significantly reduced temperature changes correlating with reduced induction of TNF- ⁇ , predictive of improved tolerability compared to Proleukin® and L2-7001®. See Figures 23-25.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002558632A CA2558632A1 (en) | 2004-03-05 | 2005-03-04 | Improved interleukin-2 muteins |
BRPI0508424-5A BRPI0508424A (en) | 2004-03-05 | 2005-03-04 | improved interleukin-2 muteins |
EP05731874A EP1730184A2 (en) | 2004-03-05 | 2005-03-04 | Improved interleukin-2 muteins |
RU2006135131/13A RU2006135131A (en) | 2004-03-05 | 2005-03-04 | IMPROVED INTERLEUKIN-2 MUTEINS |
JP2007502104A JP2007528728A (en) | 2004-03-05 | 2005-03-04 | Improved interleukin-2 muteins |
AU2005220872A AU2005220872A1 (en) | 2004-03-05 | 2005-03-04 | Improved interleukin-2 muteins |
MXPA06010017A MXPA06010017A (en) | 2004-03-05 | 2005-03-04 | Improved interleukin-2 muteins. |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55086804P | 2004-03-05 | 2004-03-05 | |
US60/550,868 | 2004-03-05 | ||
US58598004P | 2004-07-07 | 2004-07-07 | |
US60/585,980 | 2004-07-07 | ||
US64609505P | 2005-01-21 | 2005-01-21 | |
US60/646,095 | 2005-01-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005086798A2 true WO2005086798A2 (en) | 2005-09-22 |
WO2005086798A3 WO2005086798A3 (en) | 2009-02-12 |
Family
ID=34976126
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/006942 WO2005091956A2 (en) | 2004-03-05 | 2005-03-03 | In vitro test system for predicting patient tolerability of therapeutic agents |
PCT/US2005/007517 WO2005086798A2 (en) | 2004-03-05 | 2005-03-04 | Improved interleukin-2 muteins |
PCT/US2005/007303 WO2005086751A2 (en) | 2004-03-05 | 2005-03-07 | Combinatorial interleukin-2 muteins |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/006942 WO2005091956A2 (en) | 2004-03-05 | 2005-03-03 | In vitro test system for predicting patient tolerability of therapeutic agents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/007303 WO2005086751A2 (en) | 2004-03-05 | 2005-03-07 | Combinatorial interleukin-2 muteins |
Country Status (11)
Country | Link |
---|---|
US (3) | US20060234205A1 (en) |
EP (3) | EP1723251A4 (en) |
JP (3) | JP2007527242A (en) |
KR (1) | KR20070003934A (en) |
AU (3) | AU2005227263A1 (en) |
BR (3) | BRPI0508470A (en) |
CA (3) | CA2557677A1 (en) |
IL (1) | IL177876A0 (en) |
MX (2) | MXPA06010017A (en) |
RU (3) | RU2006135112A (en) |
WO (3) | WO2005091956A2 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012107417A1 (en) * | 2011-02-10 | 2012-08-16 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
US20140294758A1 (en) * | 2011-06-24 | 2014-10-02 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
RU2531936C2 (en) * | 2008-05-08 | 2014-10-27 | Аикурис Гмбх Унд Ко. Кг | Medication, intended for treatment and/or prevention of autoimmune disease and for formation of regulatory n-cells |
US20150218260A1 (en) * | 2014-02-06 | 2015-08-06 | Hoffman-La Roche Inc. | Interleukin-2 fusion proteins and uses thereof |
US9447159B2 (en) | 2011-04-29 | 2016-09-20 | Roche Glycart Ag | Immunoconjugates |
US9732134B2 (en) | 2009-01-21 | 2017-08-15 | Amgen Inc. | Method of treating graft versus host disease using IL-2 muteins |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
US9932380B2 (en) | 2013-03-14 | 2018-04-03 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
WO2018091003A1 (en) * | 2016-11-15 | 2018-05-24 | Centro De Inmunología Molecular | Method for increasing the secretion levels of interleukin 2 and proteins derived from it |
WO2019173832A3 (en) * | 2018-03-09 | 2019-10-17 | AskGene Pharma, Inc. | Cytokine prodrugs |
WO2020020783A1 (en) * | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Il2 agonists |
US10562949B2 (en) | 2012-08-10 | 2020-02-18 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US10604576B2 (en) | 2016-06-20 | 2020-03-31 | Kymab Limited | Antibodies and immunocytokines |
WO2020146221A1 (en) * | 2019-01-07 | 2020-07-16 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
US10851144B2 (en) | 2015-04-10 | 2020-12-01 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
CN112105634A (en) * | 2018-09-21 | 2020-12-18 | 信达生物制药(苏州)有限公司 | Novel interleukin-2 and uses thereof |
WO2020252418A3 (en) * | 2019-06-14 | 2021-01-21 | Cugene, Inc. | Novel interleukin-2 variants for the treatment of cancer |
US10905727B2 (en) | 2016-01-14 | 2021-02-02 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
US10988770B2 (en) | 2011-06-01 | 2021-04-27 | Intrexon Actobiotics Nv | Polycistronic expression system for bacteria |
WO2021127262A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
WO2021201615A1 (en) * | 2020-03-31 | 2021-10-07 | 한미약품 주식회사 | Novel immunoactive interleukin 2 analog |
WO2021245130A1 (en) * | 2020-06-03 | 2021-12-09 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
WO2022006380A3 (en) * | 2020-07-02 | 2022-02-24 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
AU2019343251B2 (en) * | 2018-09-21 | 2022-06-09 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin 2 and use thereof |
EP3875475A4 (en) * | 2018-12-21 | 2022-12-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Human interleukin-2 variant or derivative thereof |
US11753479B2 (en) | 2014-03-04 | 2023-09-12 | Kymab Limited | Nucleic acids encoding anti-OX40L antibodies |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
US11845801B2 (en) | 2019-06-12 | 2023-12-19 | AskGene Pharma, Inc. | IL-15 prodrugs and methods of use thereof |
US11896648B2 (en) | 2020-10-22 | 2024-02-13 | Gilead Sciences, Inc. | Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
EP2655409A4 (en) | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | Superagonists and antagonists of interleukin-2 |
MX2013009151A (en) * | 2011-02-10 | 2013-08-29 | Roche Glycart Ag | Improved immunotherapy. |
WO2014093118A1 (en) | 2012-12-11 | 2014-06-19 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for high throughput receptor:ligand identification |
WO2015042707A1 (en) | 2013-09-24 | 2015-04-02 | Medicenna Therapeutics Pte Ltd | Interleukin-2 fusion proteins and uses thereof |
JP6599310B2 (en) * | 2014-03-31 | 2019-10-30 | テルモ株式会社 | Quality evaluation method for sheet cell culture |
WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
IL289475B2 (en) * | 2014-07-21 | 2023-10-01 | Delinia Inc | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
SI3180020T1 (en) | 2014-08-11 | 2019-04-30 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
AU2016246152A1 (en) * | 2015-04-10 | 2017-11-02 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
WO2016196765A2 (en) * | 2015-06-03 | 2016-12-08 | Aelan Cell Technologies, Inc. | Companion methods and kits for il-2-based therapies and mesenchymal stem cell-based therapies |
CN108430518A (en) | 2015-09-11 | 2018-08-21 | 小利兰·斯坦福大学托管委员会 | Biological dependent quadrature cell factor/receptor pair |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
CN109071623B (en) * | 2016-05-04 | 2022-05-27 | 美国安进公司 | Interleukin-2 muteins for expansion of T regulatory cells |
BR112018073606A2 (en) | 2016-05-18 | 2019-02-26 | Cue Biopharma, Inc. | T-cell modulating multimeric polypeptides and methods of using them |
JP2019522466A (en) | 2016-05-18 | 2019-08-15 | アルバート アインシュタイン カレッジ オブ メディシン,インコーポレイティド | Mutant PD-L1 polypeptide, T cell regulatory multimeric polypeptide, and methods of use thereof |
SG11201903882VA (en) | 2016-11-08 | 2019-05-30 | Delinia Inc | Il-2 variants for the treatment of autoimmune diseases |
CN116970061A (en) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T cell modulating multimeric polypeptides and methods of use thereof |
WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | Targeted immunotolerance |
EP3596118A4 (en) | 2017-03-15 | 2021-04-07 | Cue Biopharma, Inc. | Methods for modulating an immune response |
WO2019112852A1 (en) * | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
JP2020521452A (en) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | Targeted tolerance |
JP7433051B2 (en) | 2017-06-19 | 2024-02-19 | メディシナ セラピューティクス インコーポレイテッド | Uses and methods of IL-2 superagonists, agonists, and fusions thereof |
MA49770A (en) | 2017-08-03 | 2021-05-26 | Synthorx Inc | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
KR20200086722A (en) * | 2017-11-21 | 2020-07-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Partial agonists of interleukin-2 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
SG11202007524QA (en) * | 2018-03-28 | 2020-09-29 | Ascendis Pharma Oncology Div A/S | Il-2 conjugates |
AR115024A1 (en) | 2018-03-28 | 2020-11-18 | Bristol Myers Squibb Co | INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 RECEPTOR a AND METHODS OF USE |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
CN112638406A (en) * | 2018-06-22 | 2021-04-09 | 科优基因公司 | Interleukin-2 variants and methods of use thereof |
US20220056093A1 (en) * | 2018-09-11 | 2022-02-24 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
AU2019343850B2 (en) * | 2018-09-17 | 2024-06-06 | Gi Innovation, Inc. | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof |
EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | Il-2 conjugates and methods of use thereof |
US11254736B2 (en) | 2019-02-15 | 2022-02-22 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
SG11202108281UA (en) | 2019-02-15 | 2021-08-30 | Integral Molecular Inc | Claudin 6 antibodies and uses thereof |
EP3941935A1 (en) * | 2019-03-18 | 2022-01-26 | Biontech Cell & Gene Therapies Gmbh | Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells |
JP2022533702A (en) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM-targeted immune tolerance |
JP2022536347A (en) * | 2019-06-14 | 2022-08-15 | キュージーン インコーポレイテッド | Novel interleukin-2 variants and their bifunctional fusion molecules |
WO2021059240A1 (en) | 2019-09-27 | 2021-04-01 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Treatment of celiac disease |
BR112022011513A2 (en) | 2019-12-13 | 2022-08-23 | Synthekine Inc | IL-2 ORTHHOLOGS AND METHODS OF USE |
CA3166509A1 (en) * | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
TWI790573B (en) * | 2020-03-19 | 2023-01-21 | 大陸商信達生物製藥(蘇州)有限公司 | Interleukin 2 mutein and the use thereof |
TW202203973A (en) * | 2020-04-22 | 2022-02-01 | 美商默沙東藥廠 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR βγcDIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER |
CA3169949A1 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
EP4204439A1 (en) * | 2020-08-28 | 2023-07-05 | Ascendis Pharma Oncology Division A/S | Glycosylated il-2 proteins and uses thereof |
JP2023542049A (en) * | 2020-09-01 | 2023-10-04 | 武田薬品工業株式会社 | Interleukin-2 muteins and their uses |
JP2023548311A (en) | 2020-10-29 | 2023-11-16 | ブリストル-マイヤーズ スクイブ カンパニー | Fusion proteins for the treatment of diseases |
US20240092853A1 (en) * | 2020-12-04 | 2024-03-21 | Hoffmann-La Roche Inc. | Ph-dependent mutant interleukin-2 polypeptides |
WO2023180527A1 (en) | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567611A (en) * | 1989-04-19 | 1996-10-22 | Cetus Onocology Corporation | Multifunctional M-CSF proteins and genes encoding therefor |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI82266C (en) * | 1982-10-19 | 1991-02-11 | Cetus Corp | Process for Preparation of IL-2 Mutein |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
CA1297003C (en) * | 1985-09-20 | 1992-03-10 | Jack H. Nunberg | Composition and method for treating animals |
US5643565A (en) * | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
US5683864A (en) * | 1987-11-18 | 1997-11-04 | Chiron Corporation | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
EP0378666A4 (en) * | 1988-07-05 | 1992-01-22 | Amgen Inc. | Interleukin ii analogs |
US5229109A (en) * | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
US5593671A (en) * | 1994-07-01 | 1997-01-14 | American Cyanamid Company | Method of attenuating lung capillary leak in a mammal |
US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
JP2003250820A (en) * | 2002-03-06 | 2003-09-09 | Toyoaki Murohara | Method of blood vessel regeneration and method and device for cell separation and recovery |
US6515111B1 (en) * | 1997-09-10 | 2003-02-04 | Junichi Masuyama | Monoclonal antibody which inhibits transendothelial migration of human mononuclear leukocytes |
DZ2788A1 (en) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Selective IL-2 agonists and antagonists. |
EP1151011A1 (en) * | 1999-01-29 | 2001-11-07 | Millennium Pharmaceuticals, Inc. | Anti-ccr1 antibodies and methods of use therefor |
US6960652B2 (en) * | 1999-03-30 | 2005-11-01 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
US20020041865A1 (en) * | 2000-01-20 | 2002-04-11 | Richard Austin | Methods for treating tumors |
US20030185796A1 (en) * | 2000-03-24 | 2003-10-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
EP1476180A4 (en) * | 2001-08-13 | 2005-04-20 | Univ Southern California | Interleukin-2 mutants with reduced toxicity |
US20030235556A1 (en) * | 2002-01-18 | 2003-12-25 | Chiron Corporation | Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein |
KR20070001931A (en) * | 2003-12-22 | 2007-01-04 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders |
-
2005
- 2005-03-03 US US11/073,374 patent/US20060234205A1/en not_active Abandoned
- 2005-03-03 RU RU2006135112/15A patent/RU2006135112A/en not_active Application Discontinuation
- 2005-03-03 JP JP2007501987A patent/JP2007527242A/en active Pending
- 2005-03-03 AU AU2005227263A patent/AU2005227263A1/en not_active Abandoned
- 2005-03-03 BR BRPI0508470-9A patent/BRPI0508470A/en not_active IP Right Cessation
- 2005-03-03 EP EP05724480A patent/EP1723251A4/en not_active Withdrawn
- 2005-03-03 WO PCT/US2005/006942 patent/WO2005091956A2/en active Application Filing
- 2005-03-03 KR KR1020067018789A patent/KR20070003934A/en not_active Application Discontinuation
- 2005-03-03 CA CA002557677A patent/CA2557677A1/en not_active Abandoned
- 2005-03-04 BR BRPI0508424-5A patent/BRPI0508424A/en not_active IP Right Cessation
- 2005-03-04 CA CA002558632A patent/CA2558632A1/en not_active Abandoned
- 2005-03-04 MX MXPA06010017A patent/MXPA06010017A/en not_active Application Discontinuation
- 2005-03-04 JP JP2007502104A patent/JP2007528728A/en active Pending
- 2005-03-04 EP EP05731874A patent/EP1730184A2/en not_active Ceased
- 2005-03-04 AU AU2005220872A patent/AU2005220872A1/en not_active Abandoned
- 2005-03-04 RU RU2006135131/13A patent/RU2006135131A/en not_active Application Discontinuation
- 2005-03-04 WO PCT/US2005/007517 patent/WO2005086798A2/en active Application Filing
- 2005-03-07 CA CA002564614A patent/CA2564614A1/en not_active Abandoned
- 2005-03-07 EP EP05731535A patent/EP1817332A4/en not_active Withdrawn
- 2005-03-07 BR BRPI0508455-5A patent/BRPI0508455A/en not_active IP Right Cessation
- 2005-03-07 AU AU2005220822A patent/AU2005220822A1/en not_active Abandoned
- 2005-03-07 WO PCT/US2005/007303 patent/WO2005086751A2/en active Application Filing
- 2005-03-07 JP JP2007502073A patent/JP2008509651A/en active Pending
- 2005-03-07 MX MXPA06010021A patent/MXPA06010021A/en not_active Application Discontinuation
- 2005-03-07 RU RU2006135129/13A patent/RU2006135129A/en not_active Application Discontinuation
- 2005-12-12 US US11/301,276 patent/US20060160187A1/en not_active Abandoned
- 2005-12-16 US US11/305,835 patent/US20060269515A1/en not_active Abandoned
-
2006
- 2006-09-04 IL IL177876A patent/IL177876A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567611A (en) * | 1989-04-19 | 1996-10-22 | Cetus Onocology Corporation | Multifunctional M-CSF proteins and genes encoding therefor |
Non-Patent Citations (4)
Title |
---|
ARAKAWA ET AL. BIOCHEMISTRY vol. 25, 1986, pages 8274 - 8277, XP008091210 * |
FUJITA ET AL. PROC. NATL. ACAD. SCI. USA vol. 80, 1983, pages 7437 - 7441, XP008118768 * |
MAEDA ET AL. BIOCHEM. BIOPHYS. RESEARCH COMMUNICATION vol. 115, 1983, pages 1040 - 1047, XP008119086 * |
TANIGUCHI ET AL. vol. 302, 1986, pages 305 - 310, XP002558027 * |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2531936C2 (en) * | 2008-05-08 | 2014-10-27 | Аикурис Гмбх Унд Ко. Кг | Medication, intended for treatment and/or prevention of autoimmune disease and for formation of regulatory n-cells |
US11560415B2 (en) | 2009-01-21 | 2023-01-24 | Amgen Inc. | Method of promoting regulatory T-cell proliferation |
EP2382228B1 (en) | 2009-01-21 | 2020-08-26 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
US9732134B2 (en) | 2009-01-21 | 2017-08-15 | Amgen Inc. | Method of treating graft versus host disease using IL-2 muteins |
WO2012107417A1 (en) * | 2011-02-10 | 2012-08-16 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
EP3971206A1 (en) * | 2011-02-10 | 2022-03-23 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
US9266938B2 (en) | 2011-02-10 | 2016-02-23 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
TWI666027B (en) * | 2011-02-10 | 2019-07-21 | 羅齊克雷雅公司 | Mutant interleukin-2 polypeptides |
KR101667096B1 (en) * | 2011-02-10 | 2016-10-18 | 로슈 글리카트 아게 | Mutant interleukin-2 polypetides |
TWI577801B (en) * | 2011-02-10 | 2017-04-11 | 羅齊克雷雅公司 | Mutant interleukin-2 polypeptides |
KR20130118363A (en) * | 2011-02-10 | 2013-10-29 | 로슈 글리카트 아게 | Mutant interleukin-2 polypetides |
US10323098B2 (en) | 2011-02-10 | 2019-06-18 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
EA033369B1 (en) * | 2011-02-10 | 2019-10-31 | Roche Glycart Ag | Mutant interleukin-2 polypeptides with reduced affinity to the high-affinity il-2 receptor and preserved affinity to the intermediate-affinity il-2 receptor, and use thereof |
AU2012215573B2 (en) * | 2011-02-10 | 2015-11-26 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
KR101852245B1 (en) * | 2011-02-10 | 2018-04-25 | 로슈 글리카트 아게 | Mutant interleukin-2 polypetides |
US10184009B2 (en) | 2011-02-10 | 2019-01-22 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
US11111312B2 (en) | 2011-02-10 | 2021-09-07 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
US11130822B2 (en) | 2011-04-29 | 2021-09-28 | Roche Glycart Ag | Immunoconjugates |
US10202464B2 (en) | 2011-04-29 | 2019-02-12 | Roche Glycart Ag | Immunoconjugates |
US10316104B2 (en) | 2011-04-29 | 2019-06-11 | Roche Glycart Ag | Immunoconjugates |
US9447159B2 (en) | 2011-04-29 | 2016-09-20 | Roche Glycart Ag | Immunoconjugates |
US10988770B2 (en) | 2011-06-01 | 2021-04-27 | Intrexon Actobiotics Nv | Polycistronic expression system for bacteria |
US11492383B2 (en) * | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
US20140294758A1 (en) * | 2011-06-24 | 2014-10-02 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
US11365232B2 (en) | 2012-08-10 | 2022-06-21 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US10562949B2 (en) | 2012-08-10 | 2020-02-18 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US9932380B2 (en) | 2013-03-14 | 2018-04-03 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10093711B2 (en) | 2013-03-14 | 2018-10-09 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10829535B2 (en) | 2013-03-14 | 2020-11-10 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US11976102B2 (en) | 2013-03-14 | 2024-05-07 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10562950B2 (en) | 2013-03-14 | 2020-02-18 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US20150218260A1 (en) * | 2014-02-06 | 2015-08-06 | Hoffman-La Roche Inc. | Interleukin-2 fusion proteins and uses thereof |
US11098099B2 (en) | 2014-02-06 | 2021-08-24 | Hoffmann-La Roche Inc. | Interleukin-2 fusion proteins and uses thereof |
AU2015215001B2 (en) * | 2014-02-06 | 2019-08-15 | F. Hoffmann-La Roche Ag | Interleukin-2 fusion proteins and uses thereof |
US11753479B2 (en) | 2014-03-04 | 2023-09-12 | Kymab Limited | Nucleic acids encoding anti-OX40L antibodies |
US11773175B2 (en) | 2014-03-04 | 2023-10-03 | Kymab Limited | Antibodies, uses and methods |
US11976103B2 (en) | 2015-04-10 | 2024-05-07 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10851144B2 (en) | 2015-04-10 | 2020-12-01 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10905727B2 (en) | 2016-01-14 | 2021-02-02 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
US11786567B2 (en) | 2016-01-14 | 2023-10-17 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
US10604576B2 (en) | 2016-06-20 | 2020-03-31 | Kymab Limited | Antibodies and immunocytokines |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
KR20190079636A (en) * | 2016-11-15 | 2019-07-05 | 센트로 데 인뮤놀러지아 모레큘러 | Methods for increasing secretion levels of interleukin 2 and proteins derived therefrom |
WO2018091003A1 (en) * | 2016-11-15 | 2018-05-24 | Centro De Inmunología Molecular | Method for increasing the secretion levels of interleukin 2 and proteins derived from it |
CN109952311A (en) * | 2016-11-15 | 2019-06-28 | 分子免疫中心 | Method for increasing the secretion level of proleulzin and its derived protein |
KR102525674B1 (en) | 2016-11-15 | 2023-04-25 | 센트로 데 인뮤놀러지아 모레큘러 | Method for increasing the secretion level of interleukin 2 and proteins derived therefrom |
AU2017359841B2 (en) * | 2016-11-15 | 2020-08-27 | Centro De Inmunología Molecular | Method for increasing the secretion levels of interleukin 2 and proteins derived from it |
CN109952311B (en) * | 2016-11-15 | 2022-07-01 | 分子免疫中心 | Method for increasing secretion levels of interleukin-2 and proteins derived therefrom |
CN113166220A (en) * | 2018-03-09 | 2021-07-23 | 奥美药业有限公司 | Novel cytokine prodrugs |
WO2019173832A3 (en) * | 2018-03-09 | 2019-10-17 | AskGene Pharma, Inc. | Cytokine prodrugs |
WO2020020783A1 (en) * | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Il2 agonists |
CN112105634A (en) * | 2018-09-21 | 2020-12-18 | 信达生物制药(苏州)有限公司 | Novel interleukin-2 and uses thereof |
AU2019343251B2 (en) * | 2018-09-21 | 2022-06-09 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin 2 and use thereof |
TWI801664B (en) * | 2018-09-21 | 2023-05-11 | 大陸商信達生物製藥(蘇州)有限公司 | Novel interleukin 2 and use thereof |
CN112105634B (en) * | 2018-09-21 | 2024-03-12 | 信达生物制药(苏州)有限公司 | Novel interleukin 2 and use thereof |
AU2019344875B2 (en) * | 2018-09-21 | 2021-12-23 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin 2 and use thereof |
EP3854805A4 (en) * | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin 2 and use thereof |
EP3875475A4 (en) * | 2018-12-21 | 2022-12-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Human interleukin-2 variant or derivative thereof |
WO2020146221A1 (en) * | 2019-01-07 | 2020-07-16 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
CN113924311A (en) * | 2019-01-07 | 2022-01-11 | 印希比股份有限公司 | Polypeptides comprising modified IL-2 polypeptides and uses thereof |
US11845801B2 (en) | 2019-06-12 | 2023-12-19 | AskGene Pharma, Inc. | IL-15 prodrugs and methods of use thereof |
WO2020252418A3 (en) * | 2019-06-14 | 2021-01-21 | Cugene, Inc. | Novel interleukin-2 variants for the treatment of cancer |
WO2021127262A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
US11746137B2 (en) | 2020-03-31 | 2023-09-05 | Hanmi Pharm. Co., Ltd. | Immunostimulating IL-2 analogs |
WO2021201615A1 (en) * | 2020-03-31 | 2021-10-07 | 한미약품 주식회사 | Novel immunoactive interleukin 2 analog |
WO2021245130A1 (en) * | 2020-06-03 | 2021-12-09 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
US11879001B2 (en) | 2020-06-03 | 2024-01-23 | Ascendis Pharma Oncology Division A/S | Conjugate comprising an IL-2 moiety |
WO2022006380A3 (en) * | 2020-07-02 | 2022-02-24 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
US11896648B2 (en) | 2020-10-22 | 2024-02-13 | Gilead Sciences, Inc. | Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2564614A1 (en) | 2005-09-22 |
CA2557677A1 (en) | 2005-10-06 |
US20060160187A1 (en) | 2006-07-20 |
RU2006135112A (en) | 2008-04-10 |
EP1730184A2 (en) | 2006-12-13 |
WO2005091956A3 (en) | 2005-12-08 |
WO2005086751A3 (en) | 2007-12-13 |
BRPI0508470A (en) | 2007-07-31 |
WO2005086751A2 (en) | 2005-09-22 |
US20060269515A1 (en) | 2006-11-30 |
EP1817332A4 (en) | 2009-12-02 |
MXPA06010021A (en) | 2008-03-07 |
IL177876A0 (en) | 2006-12-31 |
AU2005227263A1 (en) | 2005-10-06 |
BRPI0508424A (en) | 2007-07-24 |
MXPA06010017A (en) | 2007-03-29 |
EP1723251A4 (en) | 2008-04-23 |
KR20070003934A (en) | 2007-01-05 |
BRPI0508455A (en) | 2007-07-24 |
AU2005220872A1 (en) | 2005-09-22 |
WO2005086798A3 (en) | 2009-02-12 |
EP1817332A2 (en) | 2007-08-15 |
RU2006135129A (en) | 2008-04-10 |
RU2006135131A (en) | 2008-04-10 |
CA2558632A1 (en) | 2005-09-22 |
JP2007527242A (en) | 2007-09-27 |
WO2005091956A2 (en) | 2005-10-06 |
JP2007528728A (en) | 2007-10-18 |
JP2008509651A (en) | 2008-04-03 |
EP1723251A2 (en) | 2006-11-22 |
US20060234205A1 (en) | 2006-10-19 |
AU2005220822A1 (en) | 2005-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060269515A1 (en) | Interleukin-2 muteins | |
Cai et al. | IL‐10 enhances NK cell proliferation, cytotoxicity and production of IFN‐γ when combined with IL‐18 | |
EP1349873B1 (en) | Modulation of il-2- and il-15-mediated t cell responses | |
Zou et al. | Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells | |
CN100366742C (en) | IL-2 selective agonists and antagonists | |
Eisenman et al. | Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity | |
WO2003087320A2 (en) | Antagonists of il-21 and modulation of il-21-mediated t cell responses | |
EP2338514A1 (en) | Combined human IL-18 and pazopanib cancer treatment | |
US6433157B1 (en) | Polynucleotides encoding T-cell selective interleukin-4 agonists | |
US20120164101A1 (en) | Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer | |
US11407814B2 (en) | Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides | |
US20030004314A1 (en) | T-cell selective interleukin-4 agonists | |
JP3226918B2 (en) | Synergy of tumor necrosis factor and interleukin-4 | |
EP0912741B1 (en) | T-cell selective interleukin-4 agonists | |
US20050002899A1 (en) | Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture | |
SPLITTER | Cytokines: communication molecules that influence the process of disease | |
Reddy | Recombinant bovine interleukin-1beta and interleukin-2 mediated immunomodulation in cattle | |
MXPA98009494A (en) | Agingists of interleuquina 4 selectiva para celula |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2558632 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005220872 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007502104 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/010017 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005220872 Country of ref document: AU Date of ref document: 20050304 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005220872 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005731874 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006135131 Country of ref document: RU Ref document number: 2870/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580014421.9 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005731874 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0508424 Country of ref document: BR |